Skip to content
← All treatment topics

TREATMENT READING

Childhood Hodgkin Lymphoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

73 sections
  1. Response to initial chemotherapy
  2. Trials using interim response to titrate therapy
  3. The use of interim PET to titrate therapy
  4. End of chemotherapy response assessment
  5. Special Considerations for the Treatment of Children With Cancer
  6. Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma
  7. History of Treatment for Hodgkin Lymphoma
  8. Contemporary Treatment of Hodgkin Lymphoma
  9. Risk designation
  10. Risk-adapted treatment paradigms
  11. Histology-based therapy
  12. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
  13. Mixed-cellularity Hodgkin lymphoma
  14. Radiation Therapy
  15. Radiation volume
  16. ISRT or INRT treatment planning
  17. Radiation dose
  18. Technical considerations
  19. Role of LD-ISRT in childhood and adolescent Hodgkin lymphoma
  20. Chemotherapy
  21. Evolution of North American cooperative and consortium trial results
  22. Evolution of European multicenter trial results
  23. Accepted Risk-Adapted Treatment Strategies
  24. Classical Hodgkin lymphoma, low-risk disease
  25. Classical Hodgkin lymphoma, intermediate-risk disease
  26. Classical Hodgkin lymphoma, high-risk disease
  27. Treatment options under clinical evaluation
  28. NLPHL
  29. Treatment of Adolescents and Young Adults With Hodgkin Lymphoma
  30. Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents
  31. Chemotherapy and Targeted Therapy
  32. Checkpoint Inhibitor Therapy
  33. Chemotherapy Followed by Autologous HSCT
  34. Chemotherapy Followed by Allogeneic HSCT
  35. Involved-Site Radiation Therapy (ISRT)
  36. Response Rates for Primary Refractory Hodgkin Lymphoma
  37. Second Relapse After Initial Treatment With Autologous HSCT
  38. Treatment Options Under Clinical Evaluation
  39. Anti-CD30 chimeric antigen receptor (CAR) T-cell therapy clinical trials
  40. Other clinical trials
  41. Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy
  42. Male Gonadal Toxicity
  43. Female Gonadal Toxicity
  44. Thyroid Abnormalities
  45. Cardiac Toxicity
  46. Radiation-associated cardiovascular toxicity
  47. Anthracycline-related cardiac toxicity
  48. Subsequent Neoplasms
  49. Certain factors affect prognosis (chance of recovery) and treatment options.
  50. Childhood Hodgkin lymphoma is treated according to risk groups.
  51. Sometimes childhood Hodgkin lymphoma does not respond to treatment or comes back after treatment.
  52. Treatment Option Overview
  53. Key Points
  54. There are different types of treatment for children with Hodgkin lymphoma.
  55. Children with Hodgkin lymphoma should have their treatment planned by a team of health care providers who are experts in treating childhood cancer.
  56. The following types of treatment may be used:
  57. Chemotherapy
  58. Radiation therapy
  59. Targeted therapy
  60. Immunotherapy
  61. Surgery
  62. High-dose chemotherapy with stem cell transplant
  63. Clinical trials
  64. Proton beam radiation therapy
  65. Treatment for childhood Hodgkin lymphoma causes side effects and late effects.
  66. Patients may want to think about taking part in a clinical trial.
  67. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  68. Follow-up care may be needed.
  69. Treatment of Low-Risk Classic Childhood Hodgkin Lymphoma
  70. Treatment of Intermediate-Risk Classic Childhood Hodgkin Lymphoma
  71. Treatment of High-Risk Classic Childhood Hodgkin Lymphoma
  72. Treatment of Nodular Lymphocyte-Predominant Childhood Hodgkin Lymphoma
  73. Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Health professional · General Information About Childhood Hodgkin Lymphoma / Prognostic Factors

Response to initial chemotherapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

The rapidity of response to initial cycles of chemotherapy also appears to be prognostically important.[43-45] Response evaluation in previous generations of trials relied on computed tomography and gallium uptake; positron emission tomography (PET) scanning is now routinely used to assess early response in pediatric Hodgkin lymphoma.[46] Fluorine F 18-fludeoxyglucose PET avidity after two cycles of chemotherapy (PET2) for Hodgkin lymphoma in adults has been shown to predict treatment failure and progression-free survival.[47-49] Reduction in PET avidity after one cycle of chemotherapy was associated with a favorable EFS outcome in children with limited-stage classical Hodgkin lymphoma.[39] Additional studies in children are ongoing to assess the role of early PET-based response in modifying therapy and predicting outcome.

Sources: 43 · 45 · 46 · 47 · 49 · 39

Prognostic factors will continue to change because of risk stratification and choice of therapy, with parameters such as disease stage, bulk, systemic symptomatology, and early response to chemotherapy used to stratify therapeutic assignment.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Diagnosis and Staging Information for Childhood Hodgkin Lymphoma / Response Assessment / Interim response assessment

Trials using interim response to titrate therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Several studies have evaluated the use of interim response to titrate additional therapy:

The Pediatric Oncology Group used a response-based therapy approach consisting of dose-dense doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) for intermediate-stage and advanced-stage patients, in combination with 21 Gy involved-field radiation therapy (IFRT).[31]

Sources: 31

The Pediatric Oncology Group used a response-based therapy approach consisting of dose-dense doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) for intermediate-stage and advanced-stage patients, in combination with 21 Gy involved-field radiation therapy (IFRT).[31]

The dose-dense approach permitted reduction in chemotherapy exposure in 63% of patients who achieved a rapid early response on CT imaging after three ABVE-PC cycles.

The 5-year event-free survival (EFS) rates were comparable for rapid early responders (86%; treated with three cycles of ABVE-PC) and slow early responders (83%; treated with five cycles of ABVE-PC). All patients received 21 Gy of regional radiation therapy.

The Children's Cancer Group (CCG) (CCG-59704) evaluated response-adapted therapy featuring four cycles of the dose-intensive bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) regimen, followed by a sex-tailored consolidation, for pediatric patients with stages IIB, IIIB with bulky disease, and IV Hodgkin lymphoma.[32]

Sources: CCG-59704 · 32

The Children's Cancer Group (CCG) (CCG-59704) evaluated response-adapted therapy featuring four cycles of the dose-intensive bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) regimen, followed by a sex-tailored consolidation, for pediatric patients with stages IIB, IIIB with bulky disease, and IV Hodgkin lymphoma.[32]

For rapid early responding girls, an additional four courses of cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine (COPP/ABV) without IFRT was given in an effort to reduce breast cancer risk.

Rapid early responding boys received two cycles of ABVD followed by IFRT.

Slow early responders received four additional courses of BEACOPP and IFRT.

The Children's Cancer Group (CCG) (CCG-59704) evaluated response-adapted therapy featuring four cycles of the dose-intensive bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) regimen, followed by a sex-tailored consolidation, for pediatric patients with stages IIB, IIIB with bulky disease, and IV Hodgkin lymphoma.[32] › Slow early responders received four additional courses of BEACOPP and IFRT.

Rapid early response (defined by resolution of B symptoms and >70% reduction in tumor volume) was achieved by 74% of patients after four BEACOPP cycles. The 5-year EFS rate among the cohort was 94% (median follow-up, 6.3 years).

The COG AHOD0031 (NCT00025259), AHOD0831 (NCT01026220), and AHOD0431 (NCT00302003) trials also used interim response to titrate therapy. The AHOD0031 trial was designed to evaluate this paradigm of care by randomly assigning patients to receive either standard or response-based therapy. For more information, see the Evolution of North American cooperative and consortium trial results section.

Sources: AHOD0031 (NCT00025259) · AHOD0831 (NCT01026220) · AHOD0431 (NCT00302003) · Evolution of North American cooperative and consortium trial results

Health professional · Diagnosis and Staging Information for Childhood Hodgkin Lymphoma / Response Assessment / Interim response assessment

The use of interim PET to titrate therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

The EuroNet Hodgkin lymphoma trials use a similar early response assessment definition of PET positivity, which is a Deauville score of greater than 3 after two cycles of vincristine (Oncovin), etoposide, prednisone, and doxorubicin (Adriamycin) (OEPA).[34]

Sources: 34

GPOH studies use stringent criteria for treatment group 1 (TG1) patients that include at least 95% reduction in tumor volume or less than 2 mL residual volume on CT. Patients achieving these metrics will have radiation therapy omitted. Treatment group 2 (TG2) and treatment group 3 (TG3) patients received radiation therapy despite their potential morphological complete response (see Table 5).[7]

Sources: Table 5 · 7

The COG AHOD1331 (NCT02166463) initial therapeutics clinical trial for patients with high-risk Hodgkin lymphoma uses 18F-FDG PET assessment, graded by a 5-point visual scale or Deauville criteria after two chemotherapy cycles, to define a rapid early-responding lesion for which radiation will be omitted. A mass of any size is permitted for a complete response designation if the PET is negative. The results of using the latter criteria are not yet available, so it may not be considered standard of care.

Sources: AHOD1331 (NCT02166463)

Health professional · Diagnosis and Staging Information for Childhood Hodgkin Lymphoma / Response Assessment

End of chemotherapy response assessment

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Restaging is carried out after all initial chemotherapy is completed. It may be used to determine the need for consolidative radiation therapy. Key concepts to consider include the following:

Defining complete response. The definition of complete response may vary by cooperative group or protocol.

Defining complete response. The definition of complete response may vary by cooperative group or protocol.

The International Working Group (IWG) defined complete response for adults with Hodgkin lymphoma in terms of complete metabolic response as assessed by 18F-FDG PET, even when a persistent mass is present.[35] These criteria were endorsed in the Lugano classification, with the recommendation for a 5-point scale to assess response.[6,36] COG protocols have adopted this approach for defining complete response.

Sources: 35 · 6 · 36

Previous studies have varied in the use of findings from the clinical examination, anatomical imaging, and functional imaging to assess response. Although complete response can be defined as absence of disease by clinical examination and/or imaging studies, complete response in Hodgkin lymphoma trials is often defined by a greater than 80% reduction of disease and a change from initial positivity to negativity on functional imaging.[37] This definition is necessary in Hodgkin lymphoma because fibrotic residual disease is common, particularly in the mediastinum. In some studies, such patients are designated as having an unconfirmed complete response.

Sources: 37

Timing of PET scanning after completing therapy. Timing of PET scanning after completing therapy is an important issue.

Timing of PET scanning after completing therapy. Timing of PET scanning after completing therapy is an important issue.

For patients treated with chemotherapy alone, PET scanning is ideally performed a minimum of 3 weeks after the completion of therapy, while patients whose last treatment modality was radiation therapy should not undergo PET scanning until 8 to 12 weeks postradiation.[35]

Sources: 35

Screening frequency and overscreening.

Screening frequency and overscreening.

A COG study evaluated surveillance CT and detection of relapse in intermediate-stage and advanced-stage Hodgkin lymphoma. Most relapses occurred within the first year after therapy and were detected based on symptoms, laboratory, or physical findings. The method of detection of late relapse, whether by imaging or clinical change, did not affect overall survival. Routine use of CT at the intervals used in this study did not improve outcome.[38] Other investigations have supported the concept of reduced frequency of imaging.[39,40]

Sources: 38 · 39 · 40

Caution should be used in diagnosing relapsed or refractory disease based solely on anatomical and functional imaging because false-positive results are not uncommon.[41-43] Consequently, pathological confirmation of refractory or recurrent disease is recommended before modification of therapeutic plans.

Sources: 41 · 43

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Transplant surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Health professional

Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

History of Treatment for Hodgkin Lymphoma

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Children and adolescents with Hodgkin lymphoma have achieved long-term survival rates after treatment with radiation therapy, multiagent chemotherapy, and combined-modality therapy. In select cases of localized nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), complete surgical resection may be curative and obviate the need for cytotoxic therapy.

Treatment options for children and adolescents with Hodgkin lymphoma include the following:

Radiation therapy as a single modality.

Radiation therapy as a single modality.

Recognition of the excess adverse effects of high-dose radiation therapy on musculoskeletal development in children motivated investigations of multiagent chemotherapy alone or with lower radiation doses (15–25.5 Gy) and reduced treatment volumes (involved sites). It also led clinicians to abandon the use of radiation as a single modality except in select situations.[1-3]

Sources: 1 · 3

Radiation therapy alone may rarely be considered for adolescents and young adults with NLPHL.[4]

Sources: 4

Recognition of the excess risk of cardiovascular disease and subsequent neoplasms in adult survivors who were treated for Hodgkin lymphoma during childhood led to the restriction of radiation therapy in contemporary trials and the reduction in volume and dose when used.[5,6]

Sources: 5 · 6

Multiagent chemotherapy.

Multiagent chemotherapy.

The establishment of the non–cross-resistant combinations of mechlorethamine, vincristine (Oncovin), procarbazine, and prednisone (MOPP) developed in the 1960s and doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) developed in the 1970s made long-term survival possible for patients with advanced and unfavorable (e.g., bulky, symptomatic) Hodgkin lymphoma.[7,8] MOPP-related sequelae include a dose-related risk of infertility and subsequent myelodysplasia and leukemia.[2,9] The use of MOPP-derivative regimens substituting less leukemogenic and gonadotoxic alkylating agents (e.g., cyclophosphamide) for mechlorethamine or restricting cumulative alkylating agent dose exposure reduces this risk.[10] However, COPP-based regimens (substituting cyclophosphamide for mechlorethamine) are not commonly used in contemporary treatment protocols because of the restricted availability of procarbazine in many parts of the world. ABVD-related sequelae include a dose-related risk of cardiopulmonary toxicity related to doxorubicin and bleomycin.[11-13] The cumulative dose of these agents has been proactively restricted in pediatric patients to reduce this risk.In an effort to reduce chemotherapy-related toxicity, hybrid regimens alternating MOPP and ABVD or derivative therapy were developed. They use lower total cumulative doses of alkylators, doxorubicin, and bleomycin.[14,15]With the use of a cardioprotectant and replacing bleomycin with other agents, ABVD-based regimens are being used more in pediatric patients.[16]

Sources: 7 · 8 · 2 · 9 · 10 · 11 · 13 · 14 · 15 · 16

Etoposide has been incorporated into treatment regimens as an effective alternative to alkylating agents in an effort to reduce gonadal toxicity and enhance antineoplastic activity.[17] Etoposide-related sequelae include an increased risk of subsequent myelodysplasia and leukemia that appears to be rare when etoposide is used in restricted doses in pediatric Hodgkin lymphoma regimens.[18,19]

Sources: 17 · 18 · 19

Pediatric trials have used procarbazine-free standard backbone regimens, such as doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) in North America [20,21] and vincristine, etoposide, prednisone, doxorubicin; cyclophosphamide, vincristine, prednisone, dacarbazine (OEPA-COPDAC) in Europe.[22] Both of these regimens represent dose-dense therapies that use six drugs to maximize intensity without exceeding thresholds of toxicity.

Sources: 20 · 21 · 22

Multiagent chemotherapy alone versus combined-modality therapy.

Multiagent chemotherapy alone versus combined-modality therapy.

Treatment with non–cross-resistant chemotherapy alone offers advantages in low-income countries lacking radiation facilities and trained personnel, as well as diagnostic imaging modalities needed for clinical staging. This treatment option also avoids the potential long-term growth inhibition, organ dysfunction, and solid tumor induction associated with radiation.

Chemotherapy-alone treatment protocols usually prescribe higher cumulative doses of alkylating agent and anthracycline chemotherapy, which may produce acute- and late-treatment morbidity from myelosuppression, cardiac toxic effects, gonadal injury, and subsequent leukemia. However, more recent trials are designed to significantly reduce these risks, especially in those with chemotherapy-responsive disease.[20]

Sources: 20

In general, the use of combined chemotherapy and low-dose involved-site radiation therapy (LD-ISRT) broadens the spectrum of potential toxicities, while reducing the severity of individual drug-related or radiation-related toxicities. The results of prospective and controlled randomized trials indicate that combined-modality therapy, compared with chemotherapy alone, produces a superior event-free survival (EFS). However, because of effective second-line therapy, overall survival (OS) has not differed among the groups studied.[23,24]

Sources: 23 · 24

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

Contemporary Treatment of Hodgkin Lymphoma

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Contemporary treatment of pediatric patients with Hodgkin lymphoma uses a risk-adapted and response-based paradigm that assigns the length and intensity of therapy based on disease-related factors such as stage, number of involved nodal regions, tumor bulk, the presence of B symptoms, and early response to chemotherapy by functional and anatomical imaging. Age, sex, and histological subtype may also be considered in treatment planning.

Treatment options for childhood Hodgkin lymphoma include the following:

Radiation therapy.

Sources: Radiation therapy

Chemotherapy.

Sources: Chemotherapy

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Contemporary Treatment of Hodgkin Lymphoma

Risk designation

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Risk designation depends on favorable and unfavorable clinical features, as follows:

Favorable clinical features include localized nodal involvement in the absence of B symptoms and bulky disease. Risk factors considered in other studies include the number of involved nodal regions, presence of hilar adenopathy, size of peripheral lymphadenopathy, and extranodal extension.[25]

Sources: 25

Unfavorable clinical features include the presence of B symptoms, bulky mediastinal or peripheral lymphadenopathy, extranodal extension of disease, and advanced (stages IIIB–IV) disease.[25] In most clinical trials, bulky mediastinal lymphadenopathy is designated when the ratio of the maximum measurement of mediastinal lymphadenopathy to intrathoracic cavity on an upright chest radiograph equals or exceeds 33%. Notably, the definition of bulk is trial specific. For more information, see the Definition of bulky disease section.Pleural effusions have been shown to be an adverse prognostic finding in patients treated for low-stage Hodgkin lymphoma.[26][Level of evidence B4] The risk of relapse was 25% in patients with an effusion, compared with less than 15% in patients without an effusion. Patients with effusions were more often older (15 years vs. 14 years) and had nodular-sclerosing histology.Localized disease (stages I, II, and IIIA) with unfavorable features may be treated similarly to advanced-stage disease in some treatment protocols or treated with therapy of intermediate intensity.[25]

Sources: 25 · Definition of bulky disease · 26 · Level of evidence B4 · 25

Inconsistency in risk categorization across studies often makes comparison of study outcomes challenging.

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Contemporary Treatment of Hodgkin Lymphoma

Risk-adapted treatment paradigms

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

No single treatment approach is ideal for all pediatric and young adult patients because of differences in age-related developmental status and sex-related sensitivity to chemotherapy toxicity.

The general treatment strategy for children and adolescents with Hodgkin lymphoma is chemotherapy, with or without radiation.

The general treatment strategy for children and adolescents with Hodgkin lymphoma is chemotherapy, with or without radiation.

The rapidity and degree of response may determine the number of cycles and intensity of chemotherapy as well as the radiation dose and volume. The primary exception to this strategy is in patients with NLPHL, when surgical resection has been advocated for stage I disease with a single resectable node in the United States [27] and for any resectable disease in Europe.[28]

Sources: 27 · 28

Sex-based regimens were designed because male patients are vulnerable to gonadal toxicity from alkylating-agent chemotherapy, and female patients have a substantial risk of breast cancer after chest irradiation. In addition, males may experience a higher risk of cardiovascular disease after chest irradiation, which suggests limiting radiation exposure in males.[29]

Sources: 29

Ongoing trials for patients with favorable disease are evaluating the effectiveness of treatment with fewer cycles of combination chemotherapy alone that limit doses of anthracyclines, alkylating agents, and radiation therapy. Contemporary trials for patients with intermediate/unfavorable disease are testing whether chemotherapy and radiation therapy can be limited in patients who achieve a rapid early response to dose-intensive chemotherapy regimens. Trials have and are also testing the efficacy of regimens integrating novel, potentially less-toxic agents such as brentuximab vedotin and immune modulating therapies such as checkpoint inhibitors.[30]

Sources: 30

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Contemporary Treatment of Hodgkin Lymphoma

Histology-based therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Contemporary Treatment of Hodgkin Lymphoma / Histology-based therapy

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

The use of combination chemotherapy and/or radiation therapy can produce excellent long-term progression-free survival (PFS) and OS in patients with NLPHL.[27,31,32] Late recurrences have been reported and are typically responsive to re-treatment. Because deaths observed among individuals with this histological subtype are frequently related to complications from cytotoxic therapy or transformation to non-Hodgkin lymphoma, risk-adapted treatment assignment is particularly important for limiting exposure to agents with established dose-related toxicities.[31,32]

Sources: 27 · 31 · 32 · 31 · 32

Histological subtype may direct therapy in patients with stage I, completely resected NLPHL, whose initial treatment may be surgery alone.[27]

Sources: 27

Evidence (surgery alone for localized NLPHL):

Although treatment of adult patients with NLPHL has traditionally involved high-dose radiation alone, treatment of children originally involved chemotherapy plus LD-ISRT. Standard of care in pediatric NLPHL at present is unclear but may include chemotherapy alone or, for limited disease, complete resection of isolated nodal disease without chemotherapy. Surgical resection of localized disease produces a prolonged disease-free survival in a substantial proportion of patients, obviating the need for immediate cytotoxic therapy.[27,28,33,34] Even if cytotoxic therapy is required, the possibility of avoiding chemotherapy and radiation in prepubertal children is advantageous.

Sources: 27 · 28 · 33 · 34

Results from a single-arm Children's Oncology Group (COG) trial support the strategy of observation after surgical resection of a single node and treatment with limited chemotherapy for children with favorable stage IA or IIA NLPHL.[27][Level of evidence B1] To date, there is no evidence that this approach increases the risk of transformation to non-Hodgkin lymphoma.

Sources: 27 · Level of evidence B1

Results from a single-arm Children's Oncology Group (COG) trial support the strategy of observation after surgical resection of a single node and treatment with limited chemotherapy for children with favorable stage IA or IIA NLPHL.[27][Level of evidence B1] To date, there is no evidence that this approach increases the risk of transformation to non-Hodgkin lymphoma.

A total of 178 patients were treated with surgical resection alone for single-node disease (n = 52), chemotherapy alone after complete response (CR) to three cycles of doxorubicin, vincristine, prednisone, and cyclophosphamide (AV-PC) (n = 115), or chemotherapy with low-dose involved-field radiation therapy (LD-IFRT) (21 Gy) after incomplete response to AV-PC chemotherapy (n = 11). The 5-year EFS rate was 85.5%, and the OS rate was 100%.

The 5-year EFS rate was 77% for patients observed after total resection and 88.8% for patients treated with AV-PC chemotherapy.

Advanced-stage NLPHL is very rare. There is no consensus regarding the optimal treatment for this disease, although outcomes for patients are excellent when they are treated according to standard regimens for intermediate-risk or high-risk Hodgkin lymphoma.

Evidence (chemotherapy for NLPHL with unfavorable characteristics):

In a retrospective review of 41 patients with advanced-stage NLPHL, many different chemotherapy regimens were used; some included rituximab.[35][Level of evidence C1]

Sources: 35 · Level of evidence C1

In a retrospective review of 41 patients with advanced-stage NLPHL, many different chemotherapy regimens were used; some included rituximab.[35][Level of evidence C1]

The OS rate was 98%, with the only death resulting from a subsequent neoplasm.

In a retrospective analysis, 97 intermediate-risk patients with NLPHL were treated in COG study AHOD0031 (NCT00025259).[36]

Sources: AHOD0031 (NCT00025259) · 36

In a retrospective analysis, 97 intermediate-risk patients with NLPHL were treated in COG study AHOD0031 (NCT00025259).[36]

These patients demonstrated a higher CR rate than patients with classical histology. The 5-year EFS rate was marginally superior in patients with NLPHL (91.2%) than in patients with classical Hodgkin lymphoma (83.2%).

Most patients treated with four cycles of the ABVE-PC regimen achieved a rapid early response with a CR status and demonstrated excellent EFS and OS without IFRT. This finding suggests that the dose-dense, response-based protocol therapy designed for patients with classical Hodgkin lymphoma may have been more intensive than necessary for patients with NLPHL.

Retrospective case series report on responses with rituximab alone [37] or in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) [38] in adults with NLPHL. However, pediatric data have not been reported.

Sources: 37 · 38

A summary of treatment approaches for NLPHL can be found in Table 10. Both children and adults have a favorable outcome, particularly when the disease is localized (stage I), as it is for most patients.[27,28,33,39] In patients with NLPHL, transformation to aggressive large B-cell lymphoma rarely occurs. When it does, it substantially increases the risk of mortality.[40] In adults with NLPHL, a variant immunoarchitectural pattern has been associated with a higher risk of progression to aggressive lymphoma and more advanced disease.[41] Among long-term survivors of NLPHL, death is more likely to result from treatment-related toxicity (both acute and long-term) than from lymphoma.[42,43]

Sources: Table 10 · 27 · 28 · 33 · 39 · 40 · 41 · 42 · 43

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Contemporary Treatment of Hodgkin Lymphoma / Histology-based therapy

Mixed-cellularity Hodgkin lymphoma

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

In addition to variable responses by histology for NLPHL, differences by mixed-cellularity histology have also been observed. COG investigators reported a 4-year EFS rate of 95.2% for children with stage I or stage II mixed-cellularity histology treated with minimal AV-PC therapy (and only rarely requiring radiation therapy). This EFS rate was significantly better than the 75.8% EFS rate for patients who had nodular-sclerosing histology (P = .008).[44]

Sources: 44

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

Radiation Therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

As previously mentioned, most newly diagnosed children are treated with risk-adapted chemotherapy, either alone or in combination with consolidative radiation therapy. Radiation therapy volumes can vary and have protocol-specific definitions, but they generally encompass lymph node sites initially involved at the time of diagnosis, without extensive inclusion of uninvolved regions, or positron emission tomography (PET)-avid sites at either interim or end-of-therapy assessment. Radiation therapy field reductions are made to account for tumor regression with chemotherapy.[45]

Sources: 45

One study investigated the effects of central review of the interim fluorine F 18-fludeoxyglucose (18F-FDG) PET–computed tomography (CT) scan response (iPET) assessment on treatment allocation in the risk-based, response-adapted COG AHOD1331 (NCT02166463) study for pediatric patients with high-risk Hodgkin lymphoma. The study evaluated the results of 573 patients after two cycles of chemotherapy. There was good agreement between central and institutional iPET analysis, with a concordance rate of 89.7% (514 of 573). Of 126 patients who were considered iPET positive by institutional review, 30% were found to be iPET negative by central review. Thus, these patients could avoid being treated with radiation therapy. Conversely, of 447 patients who were considered iPET negative by institutional review, 4.7% were considered positive by central review, which led to these patients receiving radiation therapy.[46]

Sources: AHOD1331 (NCT02166463) · 46

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Radiation Therapy

Radiation volume

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

With advancements in systemic therapy, radiation therapy field definitions have become increasingly restricted. Radiation therapy is no longer needed to sterilize all disease. Advances in radiological imaging allow for a more precise radiation target definition. With effective chemotherapy and contemporary treatments using lower radiation doses (<21 Gy) and reduced volumes (ISRT), contralateral uninvolved sites are not irradiated.

General trends in radiation treatment volume are summarized as follows:

Historical regional radiation therapy fields (e.g., mantle, subtotal, or total nodal) have been replaced by involved-nodal radiation therapy (INRT) or ISRT. In select situations, such as adolescents and young adults treated with radiation alone for NLPHL, IFRT is used.

INRT defines the treatment volume using the prechemotherapy PET-CT scan that is obtained with the patient in a position similar to the position to be used at the time of radiation therapy. This volume is later contoured onto the postchemotherapy-planning CT scan. The final treatment volume only includes the initially involved nodes with a margin, typically 2 cm.[47-49] The subsequent EuroNet-PHL-C2 trial employs INRT.

Sources: 47 · 49

ISRT, used in contemporary COG trials, is used when optimal prechemotherapy imaging (PET-CT in a position similar to the position to be used at the time of radiation therapy) is not available to the radiation oncologist. Because the delineation of the area of involvement is less precise, a somewhat larger treatment volume is contoured than for INRT, typically at least 2 cm around the nodes where the lymphoma was located before chemotherapy was given. The exact volume will depend on the individual case scenario.[45] There are several situations in which this definition is further modified, such as when inappropriately large volumes of sensitive normal tissues might be exposed.[50]

Sources: 45 · 50

Modified involved-field radiation therapy is the term used in the EuroNet-PHL-C1 trial to describe treatment volumes that contain the involved lymph node(s) as seen before chemotherapy plus radiation planning margins of 1 cm to 2 cm, depending on the area of involvement. These volumes are comparable to ISRT fields, although the development preceded the widespread availability of CT-based planning.

Breast-sparing radiation therapy plans using proton therapy are under evaluation to determine whether there is a statistically significant reduction in dose.[51] Ongoing studies seek to determine whether doses to other critical organs, such as the heart and lungs, can be reduced with proton therapy, without compromising survival outcomes.[52][Level of evidence C1] Long-term results are pending.

Sources: 51 · 52 · Level of evidence C1

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Radiation Therapy / Radiation volume

ISRT or INRT treatment planning

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Radiation therapy planning that uses CT scans obtained during the simulation procedure is a requirement for contemporary INRT or ISRT. Fusion of staging imaging (CT or PET-CT) with the planning CT dataset can facilitate delineation of the treatment volume. Radiation therapy planning scans that encompass the full extent of organs at risk (e.g., lungs) are important so that normal tissue exposures can be calculated accurately.

Definitions that are important in planning radiation therapy include the following:

Prechemotherapy or presurgery gross tumor volume (GTV): Imaging abnormalities of nodal or non-nodal tissues at initially involved sites.

Postchemotherapy GTV: Imaging abnormalities at initially involved sites that remain abnormal after chemotherapy.

Postchemotherapy clinical target volume (CTV): Abnormal tissues originally involved with lymphoma but taking into account the reduction in the axial (transverse) diameter that has occurred with chemotherapy. This delineation requires consideration of the expected routes of disease spread and the quality of pretreatment imaging.

Internal target volume (ITV): Encompasses the CTV, with an added margin to account for variation in shape and motion within the patient (e.g., breathing).

Planning target volume (PTV): Encompasses the ITV or CTV and accounts for variation in daily setup for radiation; generally, 0.5 cm to 1 cm.

Boost radiation therapy: Some protocols, such as the EuroNet-PHL-C1 protocol, give additional radiation therapy (a boost) to sites with a poor response and/or bulky residual disease after initial chemotherapy. These volumes were determined after completion of all chemotherapy. This approach is sometimes used for patients with residual areas of PET avidity after chemotherapy.

Organ at risk determination and dose constraints: Because of the importance of long-term tissue injury after radiation, the dose to normal tissues is kept as low as reasonably achievable while adequately treating the PTV. Some specific organ radiation dose tolerances guide these decisions, and these organs are considered organs at risk.

The treatment volume for unfavorable or advanced disease is somewhat variable and often protocol-specific. Large-volume radiation therapy may compromise organ function and limit the intensity of second-line therapy if relapse occurs. In patients with intermediate or advanced disease, who often have multifocal/extranodal disease, the current standard of therapy includes postchemotherapy ISRT that limits radiation exposure to large portions of the body.[45,50] For example, in the AHOD0031 trial, radiation therapy was given to involved sites at diagnosis,[20] but in the AHOD1331 trial, it was given to bulky mediastinal disease and to slow responding disease sites (based on interim PET scan).[53] There is emerging evidence for omitting radiation therapy entirely in patients who have a complete, PET-based response. Thus, in the S1826 trial, radiation therapy was given only to patients with residual, metabolically active posttherapy sites as defined on PET.[30]

Sources: 45 · 50 · 20 · 53 · 30

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Radiation Therapy

Radiation dose

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

The dose of radiation also varies and is often protocol specific.

General considerations regarding radiation dose include the following:

Doses of 15 Gy to 25 Gy are typically used, with modifications based on patient age, the presence of bulky or residual (postchemotherapy) disease, and normal tissue concerns. Contemporary studies (Euronet-PHL-C1 and C2, AHOD1331, AHOD1721, and S1826) also allow for consideration of dose augmentation to 30 Gy to 36 Gy to residual PET-avid (Deauville score of 4 and, rarely, 5) sites after chemotherapy. This is because of the continued relapses in involved sites even after combined-modality therapy.[20,30,54]

Sources: 20 · 30 · 54

Some protocols have prescribed a boost of 5 Gy to 10 Gy in regions with suboptimal response to chemotherapy.[55] This approach has not been formally evaluated to quantitate the risk-benefit relationship, and it clearly increases the risk of radiation-associated late effects on heart, lungs, and breast tissues.

Sources: 55

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Radiation Therapy

Technical considerations

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Technical considerations for the use of radiation therapy to treat Hodgkin lymphoma include the following:

A linear accelerator with a beam energy of 6 mV is desirable because of its penetration, well-defined edge, and homogeneity throughout an irregular treatment field.

Three-dimensional conformal radiation therapy (3-D CRT) or intensity-modulated radiation therapy (IMRT) are standard techniques in the treatment of lymphoma. Appropriate CT-based, image-guided treatment planning and delivery are standard, preferably with fusion of staging CT and PET imaging with radiation therapy planning CT datasets to delineate the target volumes.[45]

Sources: Three-dimensional conformal radiation therapy · intensity-modulated radiation therapy · 45

Data are accumulating regarding the efficacy of IMRT and the decrease in median dose to normal surrounding tissues. Some uncertainty exists about the potential for increased late effects from IMRT, particularly subsequent neoplasms, because a larger area of the body receives a low dose compared with conventional techniques (although the mean dose to a volume may be decreased).

Proton therapy is being investigated and may further decrease the mean dose to the surrounding normal tissue compared with IMRT or 3-D CRT, without increasing the volume of normal tissue receiving lower-dose radiation.[56]

Sources: 56

Individualized immobilization devices are preferable for young children to ensure accuracy and reproducibility.

Attempts should be made to exclude or position breast tissue under the lung/axillary shielding.

When the decision is made to include some or all of a critical organ (such as liver, kidney, or heart) in the radiation field, then normal tissue constraints are critical, depending on the chemotherapy used and patient age.

Whole-lung irradiation (~10 Gy), with partial transmission blocks or intensity modulation, was historically a consideration in the setting of overt pulmonary nodules that had not achieved a CR.[20,21,55] However, it may be used in exceptional situations.

Sources: 20 · 21 · 55

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Radiation Therapy

Role of LD-ISRT in childhood and adolescent Hodgkin lymphoma

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Because all children and adolescents with Hodgkin lymphoma receive chemotherapy, an important question is whether patients who achieve a rapid early response or a CR to chemotherapy require radiation therapy. Conversely, the judicious use of LD-ISRT may permit a reduction in the intensity or duration of chemotherapy below toxicity thresholds that would not be possible if single-modality chemotherapy was used, thus decreasing overall acute and late toxicities.

The treatment approach for pediatric Hodgkin lymphoma should focus on maximizing disease control and minimizing risks of late toxicity associated with both radiation therapy and chemotherapy. Key points to consider regarding the role of radiation include the following:

The use of LD-IFRT or ISRT in children with Hodgkin lymphoma may permit reduction in duration or intensity of chemotherapy and, as a result, dose-related toxicity of anthracyclines, alkylating agents, and bleomycin. This treatment may preserve cardiopulmonary and gonadal function and reduce the risk of subsequent leukemia.

Radiation has been used as an adjunct to multiagent chemotherapy in clinical trials for low-, intermediate-, and high-risk pediatric Hodgkin lymphoma. The goal is to reduce risk of relapse in initially involved sites that do not show sufficient early or end-of-therapy responses to treatment, with the intent of preventing toxicity associated with second-line therapy.Compared with chemotherapy alone, adjuvant radiation has, in most studies, produced a superior EFS for children with intermediate-risk and high-risk Hodgkin lymphoma who achieve a CR to multiagent chemotherapy. But it does not clearly improve OS because of the success of second-line therapy.[24] However, the intermediate-risk Hodgkin lymphoma study (AHOD0031 [NCT00025259]) did not show a benefit for IFRT in patients who achieved a rapid CR to chemotherapy (defined as >60% reduction in 2-dimensional tumor burden after two cycles and metabolic remission and >80% reduction after four cycles). The 4-year EFS rate was 87.9% for patients with rapid responses who were randomly assigned to IFRT versus 84.3% (P = .11) for patients with rapid responses who were not assigned to IFRT. The OS rate was 98.8% in both groups.[20] In a subset analysis of patients with anemia and bulky limited-stage disease, the EFS rate was 89.3% for patients with rapid early responses or complete remissions who received IFRT, compared with 77.9% for patients who did not receive IFRT (P = .019).[57][Level of evidence B1]Adjuvant radiation therapy may be associated with an increased risk of late effects or mortality.[58]

Sources: 24 · AHOD0031 [NCT00025259] · 20 · 57 · Level of evidence B1 · 58

Radiation consolidation may facilitate local disease control in individuals with refractory or recurrent disease, especially in those who have limited or bulky sites of disease progression/recurrence or persistent disease that does not completely respond to chemotherapy.[59,60]

Sources: 59 · 60

The radiation dose to breast, heart, thyroid, and lung tissue received by patients in contemporary COG trials is 55% to 85% lower than the dose received by survivors analyzed in the Childhood Cancer Survivors Study (CCSS). This finding should be considered when estimating the risk of late toxicity associated with modern radiation therapy.[61] However, a Stanford report identified a significant risk of breast cancer in children with Hodgkin lymphoma despite being treated with low-dose radiation therapy. The regimen used from 1970 to 1990 prescribed IFRT of 15 Gy to 25.5 Gy. At a median follow-up of 20.6 years, 18 of 110 children treated with radiation therapy in this dose range developed one or more subsequent malignant neoplasms, including 6 patients who developed breast carcinomas.[62]

Sources: 61 · 62

Finally, an inherent assumption is made in a trial comparing chemotherapy alone versus chemotherapy and radiation that the effect of radiation on EFS will be uniform across all patient subgroups. However, it is not clear how histology, presence of bulky disease, presence of B symptoms, or other variables affect the efficacy of postchemotherapy radiation.

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

Chemotherapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Many chemotherapy combinations have been used to effectively treat pediatric patients with Hodgkin lymphoma. Many of the agents in original MOPP and ABVD regimens continue to be used. Etoposide has been incorporated into some pediatric treatment regimens as an effective alternative to alkylating agents, in an effort to reduce gonadal toxicity and enhance antineoplastic activity. Current treatment approaches for pediatric patients with Hodgkin lymphoma use procarbazine-free standard backbone regimens, such as ABVE-PC in North America [20,21] and OEPA-COPDAC in Europe.[22] Both of these regimens represent dose-dense therapies that use six drugs to maximize intensity without exceeding thresholds of toxicity. In North America, pediatric patients with Hodgkin lymphoma are treated with ABVD-based regimens. However, bleomycin has been replaced by other agents (i.e., brentuximab vedotin or nivolumab), and the cardioprotectant dexrazoxane has been used to reduce the risk of late effects.

Sources: 20 · 21 · 22

Combination chemotherapy regimens used in trials are summarized in Table 6.

Sources: Table 6

Table 6. Chemotherapy Regimens for Children and Adolescents With Hodgkin Lymphoma
NameDrugsDosageRouteDays
IV = intravenous; PO = oral.
aABVE-PC modifications during the P9425 study included reducing bleomycin to 5 units/m2 on day 0 and administering prednisone on days 0 to 7 (instead of days 0–9). In subsequent studies, doxorubicin dose was reduced to 25 mg/m2 in all trials, and for high-risk Hodgkin lymphoma, use of cyclophosphamide was increased to 600 mg/m2 on days 1 and 2.
COPDAC [22]Cyclophosphamide600 mg/m2IV1, 8
Vincristine (Oncovin)1.4 mg/m2IV1, 8
Prednisone40 mg/m2PO1–15
Dacarbazine250 mg/m2IV1–3
CAPDAC [63]Brentuximab vedotin substituted for vincristine in COPDAC1.2 mg/kgIV1, 8
OEPA [22]Vincristine (Oncovin)1.5 mg/m2IV1, 8, 15
Etoposide125 mg/m2IV3–6
Prednisone60 mg/m2PO1–15
Doxorubicin (Adriamycin)40 mg/m2IV1, 15
AEPA [63]Brentuximab vedotin substituted for vincristine in OEPA1.2 mg/kgIV1, 8, 15
ABVD [8]Doxorubicin (Adriamycin)25 mg/m2IV1, 15
Bleomycin10 units/m2IV1, 15
Vinblastine6 mg/m2IV1, 15
Dacarbazine375 mg/m2IV1, 15
N-AVD [30]Doxorubicin (Adriamycin)25 mg/m2IV1, 15
Vinblastine6 mg/m2IV1, 15
Dacarbazine375 mg/m2IV1, 15
NivolumabAge 12–17 y: 3 mg/kg (240 mg maximum); age 18 y or older: 240 mgIV1, 15
ABVE-PC a [21]Doxorubicin (Adriamycin)30 mg/m2IV0, 1
Bleomycin10 units/m2IV0, 7
Vincristine (Oncovin)1.4 mg/m2 (maximum dose, 2.8 mg/m2)IV0, 7
Etoposide75 mg/m2IV0–4
Prednisone40 mg/m2PO0–9
Cyclophosphamide800 mg/m2IV0
Bv-AVE-PC (bleomycin omitted and brentuximab vedotin added to the ABVE-PC regimen) [53]Brentuximab vedotin1.8 mg/kgIV1
Vincristine1.4 mg/m2 (maximum dose, 2.8 mg/m2)IV8
BEACOPP [64]Bleomycin10 units/m2IV7
Etoposide200 mg/m2IV0–2
Doxorubicin (Adriamycin)35 mg/m2IV0
Cyclophosphamide1,200 mg/m2IV1, 8
Vincristine (Oncovin)2 mg/m2IV7
Prednisone40 mg/m2PO0–13
Procarbazine100 mg/m2PO0–6
CVP [65]Cyclophosphamide500 mg/m2IV1
Vinblastine6 mg/m2IV1, 8
Prednisolone40 mg/m2PO1–8
AV-PC [27,44]Doxorubicin (Adriamycin)25 mg/m2IV1, 2
Vincristine1.4 mg/m2 (maximum dose, 2.8 mg/m2)IV1, 8
Prednisone20 mg/m2PO1–7
Cyclophosphamide600 mg/m2IV1, 2

Sources: 22 · 63 · 22 · 63 · 8 · 30 · 21 · 53 · 64 · 65 · 27 · 44

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Chemotherapy

Evolution of North American cooperative and consortium trial results

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

A series of North American trials have evaluated response-based and risk-adapted therapy.

Evidence (response-based and risk-adapted therapy):

The Pediatric Oncology Group organized two trials featuring response-based, risk-adapted therapy with ABVE [66] for patients with favorable low-stage disease and dose-dense ABVE-PC for patients with unfavorable advanced-stage disease in combination with 21 Gy IFRT.[21]

Sources: 66 · 21

The Pediatric Oncology Group organized two trials featuring response-based, risk-adapted therapy with ABVE [66] for patients with favorable low-stage disease and dose-dense ABVE-PC for patients with unfavorable advanced-stage disease in combination with 21 Gy IFRT.[21]

Children and adolescents with low-risk Hodgkin lymphoma (stages I, IIA, IIIA1) treated with IFRT (25.5 Gy) after achieving CR to two cycles of doxorubicin, bleomycin, vincristine, and etoposide (DBVE) had outcomes comparable to those not in CR after two cycles of DBVE who were then treated with a total of four cycles of DBVE and IFRT (25.5 Gy). This response-dependent approach permitted reduction in chemotherapy exposure in 45% of patients.[66]

Sources: 66

A dose-dense, early response–based treatment approach with ABVE-PC permitted reduction in chemotherapy exposure in 63% of patients who achieved a rapid early response after three ABVE-PC cycles.[21][Level of evidence B1]

Sources: 21 · Level of evidence B1

The 5-year EFS rate was comparable for patients with rapid early responses (86%) and slow early responses (83%) who were treated with three and five cycles of ABVE-PC, respectively, followed by radiation therapy (21 Gy). Patients who received dexrazoxane had more hematological and pulmonary toxicity.[21]

Sources: 21

Although etoposide is associated with an increased risk of therapy-related acute myeloid leukemia with 11q23 abnormalities, the risk is very low in those treated with ABVE or ABVE-PC without dexrazoxane.[18,67]

Sources: 18 · 67

A large COG study (COG-59704) evaluated response-adapted therapy featuring four cycles of a dose-intensive regimen of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP), followed by a sex-tailored consolidation for pediatric patients with stages IIB, IIIB with bulky disease, and IV Hodgkin lymphoma.[64][Level of evidence B4] For girls with rapid early responses, an additional four courses of COPP/ABV (without IFRT) were given. Boys with rapid early responses received two cycles of ABVD followed by IFRT. Patients with slow early responses received four additional courses of BEACOPP and IFRT. Eliminating IFRT from the girls' therapy was intended to reduce the risk of breast cancer. Key findings include the following:[64]However, infectious complications during therapy and the long-term risks of infertility and subsequent neoplasms undermine this approach as an optimal treatment, particularly in light of newer and safer strategies.

Sources: COG-59704 · 64 · Level of evidence B4 · 64

A large COG study (COG-59704) evaluated response-adapted therapy featuring four cycles of a dose-intensive regimen of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP), followed by a sex-tailored consolidation for pediatric patients with stages IIB, IIIB with bulky disease, and IV Hodgkin lymphoma.[64][Level of evidence B4] For girls with rapid early responses, an additional four courses of COPP/ABV (without IFRT) were given. Boys with rapid early responses received two cycles of ABVD followed by IFRT. Patients with slow early responses received four additional courses of BEACOPP and IFRT. Eliminating IFRT from the girls' therapy was intended to reduce the risk of breast cancer. Key findings include the following:[64]However, infectious complications during therapy and the long-term risks of infertility and subsequent neoplasms undermine this approach as an optimal treatment, particularly in light of newer and safer strategies.

Rapid early response (defined by resolution of B symptoms and >70% reduction in tumor volume) was achieved by 74% of patients after four cycles of BEACOPP.

The 5-year EFS rate was 94%, with a median follow-up time of 6.3 years.

Early intensification followed by less-intense response-based therapy resulted in high EFS.

The Stanford, St. Jude Children's Research Hospital, and Boston Consortium administered a series of risk-adapted trials over the last 20 years. Key findings include the following:

The Stanford, St. Jude Children's Research Hospital, and Boston Consortium administered a series of risk-adapted trials over the last 20 years. Key findings include the following:

Nonalkylating-agent chemotherapy (e.g., methotrexate or etoposide) instead of alkylating-agent chemotherapy results in an inferior EFS among patients with unfavorable clinical presentations.[68,69]

Sources: 68 · 69

The combination of vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) is an effective regimen (10-year EFS rate, 89%) for children and adolescents with favorable-risk disease (low-stage NLPHL and classical Hodgkin lymphoma without B symptoms or bulky disease) when used in combination with response-based LD-IFRT (15–25.5 Gy).[70]

Sources: 70

Patients with favorable-risk Hodgkin lymphoma treated with four cycles of VAMP chemotherapy alone who achieved an early CR had a comparable 5-year EFS rate to those treated with four cycles of VAMP chemotherapy plus 25.5 Gy IFRT (89% vs. 88%).[71]

Sources: 71

The COG AHOD0031 (NCT00025259) study enrolled 1,712 patients in a randomized controlled trial to evaluate the role of early chemotherapy response in tailoring subsequent therapy in pediatric intermediate-risk Hodgkin lymphoma. Intermediate-risk Hodgkin lymphoma was defined as Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulky disease, and IA or IIA with bulky disease. All patients received two cycles of ABVE-PC followed by response evaluation.[20]Key 4-year OS and EFS outcomes from this trial include the following:An analysis of patterns of failure among patients whose disease relapsed while enrolled in the AHOD0031 (NCT00025259) study demonstrated that first relapses occurred more often within the previously irradiated field and within initially involved sites of disease, including both bulky and nonbulky sites.[54]

Sources: AHOD0031 (NCT00025259) · 20 · AHOD0031 (NCT00025259) · 54

The COG AHOD0031 (NCT00025259) study enrolled 1,712 patients in a randomized controlled trial to evaluate the role of early chemotherapy response in tailoring subsequent therapy in pediatric intermediate-risk Hodgkin lymphoma. Intermediate-risk Hodgkin lymphoma was defined as Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulky disease, and IA or IIA with bulky disease. All patients received two cycles of ABVE-PC followed by response evaluation.[20]Key 4-year OS and EFS outcomes from this trial include the following:An analysis of patterns of failure among patients whose disease relapsed while enrolled in the AHOD0031 (NCT00025259) study demonstrated that first relapses occurred more often within the previously irradiated field and within initially involved sites of disease, including both bulky and nonbulky sites.[54]

Patients with rapid early responses (defined by CT imaging after two cycles) received two additional ABVE-PC cycles, followed by CR evaluation.

The COG AHOD0031 (NCT00025259) study enrolled 1,712 patients in a randomized controlled trial to evaluate the role of early chemotherapy response in tailoring subsequent therapy in pediatric intermediate-risk Hodgkin lymphoma. Intermediate-risk Hodgkin lymphoma was defined as Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulky disease, and IA or IIA with bulky disease. All patients received two cycles of ABVE-PC followed by response evaluation.[20]Key 4-year OS and EFS outcomes from this trial include the following:An analysis of patterns of failure among patients whose disease relapsed while enrolled in the AHOD0031 (NCT00025259) study demonstrated that first relapses occurred more often within the previously irradiated field and within initially involved sites of disease, including both bulky and nonbulky sites.[54] › Patients with rapid early responses (defined by CT imaging after two cycles) received two additional ABVE-PC cycles, followed by CR evaluation.

Patients with rapid early responses with CR at the end of chemotherapy (based on CT imaging and negative PET or gallium scans) were randomly assigned to receive either IFRT or no additional therapy.

Patients with rapid early responses with less than a CR were nonrandomly assigned to IFRT.

The COG AHOD0031 (NCT00025259) study enrolled 1,712 patients in a randomized controlled trial to evaluate the role of early chemotherapy response in tailoring subsequent therapy in pediatric intermediate-risk Hodgkin lymphoma. Intermediate-risk Hodgkin lymphoma was defined as Ann Arbor stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulky disease, and IA or IIA with bulky disease. All patients received two cycles of ABVE-PC followed by response evaluation.[20]Key 4-year OS and EFS outcomes from this trial include the following:An analysis of patterns of failure among patients whose disease relapsed while enrolled in the AHOD0031 (NCT00025259) study demonstrated that first relapses occurred more often within the previously irradiated field and within initially involved sites of disease, including both bulky and nonbulky sites.[54]

Patients with slow early responses were randomly assigned to receive two additional ABVE-PC cycles with or without two cycles of dexamethasone, etoposide, cisplatin, and cytarabine (DECA). All patients with slow early responses were assigned to receive IFRT.

Early response was an important prognostic factor. The overall EFS rate was 85.0% and significantly higher (P < .001) for patients with rapid early responses (86.9%) than for patients with slow early responses (77.4%).

The OS rate was 97.8% and significantly higher (P < .001) for patients with rapid early responses (98.5%) than for patients with slow early responses (95.3%).

Approximately 45% of patients had rapid early responses and achieved CR by the end of chemotherapy. For this population, the EFS rate did not differ significantly (P = .11) among those who were randomly assigned to IFRT (87.9%) versus no IFRT (84.3%). The OS rate was 98.8% (95% confidence interval [CI], 96.8%–99.5%) for those receiving IFRT and 98.8% (95% CI, 96.9%–99.6%) for those receiving chemotherapy alone.

Despite achieving rapid early response or CR, stage I or stage II patients with bulky mediastinal adenopathy and anemia had significantly better EFS when randomly assigned to IFRT after four cycles of ABVE-PC.[57]

Sources: 57

Approximately 20% of patients had slow early responses. For this population, the EFS rate did not differ significantly (P = .11) among those who were randomly assigned to DECA (79.3%) versus no DECA (75.2%).

Study results confirm the prognostic significance of early chemotherapy response and support the safety of no IFRT, based on rapid early response with CR by the end of chemotherapy.

The COG AHOD0431 (NCT00302003) study used a response-directed treatment strategy for children and adolescents with stage I and stage IIA, nonbulky disease. Chemotherapy sensitivity was assessed by 18F-FDG PET response after one and three cycles of AV-PC chemotherapy. LD-IFRT (21 Gy) was administered only to patients who did not achieve a complete remission after chemotherapy. The protocol also incorporated a standardized salvage regimen (vinorelbine and ifosfamide plus dexamethasone, etoposide, cisplatin, and cytarabine) for low-risk recurrences (defined as stage I/II, nonbulky disease, regardless of time to relapse) after treatment with chemotherapy alone.[44]

Sources: AHOD0431 (NCT00302003) · 44

The COG AHOD0431 (NCT00302003) study used a response-directed treatment strategy for children and adolescents with stage I and stage IIA, nonbulky disease. Chemotherapy sensitivity was assessed by 18F-FDG PET response after one and three cycles of AV-PC chemotherapy. LD-IFRT (21 Gy) was administered only to patients who did not achieve a complete remission after chemotherapy. The protocol also incorporated a standardized salvage regimen (vinorelbine and ifosfamide plus dexamethasone, etoposide, cisplatin, and cytarabine) for low-risk recurrences (defined as stage I/II, nonbulky disease, regardless of time to relapse) after treatment with chemotherapy alone.[44]

At 4 years, the OS rate was 99.6%, with 49.0% in remission after treatment with minimal chemotherapy alone and 88.8% in remission without receiving high-dose chemotherapy with stem cell rescue or more than 21 Gy of IFRT.[44]

Sources: 44

Factors predicting favorable EFS after a limited chemotherapy response-based approach included mixed-cellularity histology, low erythrocyte sedimentation rate, and negative 18F-FDG PET after one cycle.[44]

Sources: 44

Extended follow-up of this trial confirmed a significantly higher rate of relapse among patients with a slow early response by PET after one cycle, which was mitigated by adding 21 Gy of IFRT.[72][Level of evidence B4]

Sources: 72 · Level of evidence B4

The COG AHOD0431 (NCT00302003) study used a response-directed treatment strategy for children and adolescents with stage I and stage IIA, nonbulky disease. Chemotherapy sensitivity was assessed by 18F-FDG PET response after one and three cycles of AV-PC chemotherapy. LD-IFRT (21 Gy) was administered only to patients who did not achieve a complete remission after chemotherapy. The protocol also incorporated a standardized salvage regimen (vinorelbine and ifosfamide plus dexamethasone, etoposide, cisplatin, and cytarabine) for low-risk recurrences (defined as stage I/II, nonbulky disease, regardless of time to relapse) after treatment with chemotherapy alone.[44] › Extended follow-up of this trial confirmed a significantly higher rate of relapse among patients with a slow early response by PET after one cycle, which was mitigated by adding 21 Gy of IFRT.[72][Level of evidence B4]

For patients with rapid early responses, the 10-year PFS rate was 96.6% with IFRT and 84.1% without IFRT (P = .10).

For patients with slow early responses, the 10-year PFS rate was 80.9% with IFRT and 64% without IFRT (P =.03).

Among the 90 patients with rapid early responses who did not receive IFRT, all 14 relapses included an initial disease site.

Among the 45 patients with slow early responses who did not receive IFRT, 14 of the 16 relapses occurred in the initial disease site.

This 3-year study was amended during the second year. All patients with equivocal or positive PET findings after one cycle were treated with IFRT, even if they achieved a CR after three cycles.

In the COG AHOD1331 (NCT02166463) phase III study, 587 eligible patients with high-risk Hodgkin lymphoma were randomly assigned to receive ABVE-PC or Bv-AVE-PC, a regimen that incorporates brentuximab vedotin, omits bleomycin, and reduces vincristine to one dose per treatment course (see Table 6). Patients aged 2 to 21 years with stage IIB with bulk, stage IIIB, and stage IV Hodgkin lymphoma were eligible.[53]

Sources: AHOD1331 (NCT02166463) · Table 6 · 53

In the COG AHOD1331 (NCT02166463) phase III study, 587 eligible patients with high-risk Hodgkin lymphoma were randomly assigned to receive ABVE-PC or Bv-AVE-PC, a regimen that incorporates brentuximab vedotin, omits bleomycin, and reduces vincristine to one dose per treatment course (see Table 6). Patients aged 2 to 21 years with stage IIB with bulk, stage IIIB, and stage IV Hodgkin lymphoma were eligible.[53]

After a median follow-up period of 42.1 months, the 3-year EFS rates were 92.1% (95% CI, 88.4%–94.7%) for patients who received Bv-AVE-PC and 82.5% (95% CI, 77.4%–86.5%; P = .0002) for patients who received ABVE-PC.

The cumulative incidence of relapse was significantly lower for patients who received Bv-AVE-PC (7.5%; 95% CI, 4.9%–10.9%) than for patients who received ABVE-PC (17.1%; 95% CI, 12.9%–21.8%).

Radiation therapy was administered to patients with slow-responding lesions confirmed by PET2 imaging (defined as a five-point scale score >3) and to patients with any large mediastinal masses. The percentage of patients who received radiation therapy was similar between the two arms of the study (52.7% for Bv-AVE-PC and 55.7% for ABVE-PC).

Rates of febrile neutropenia, infection complications, and neuropathy were similar between the two arms of the study.

In the group of patients who received the novel agent brentuximab vedotin, health-related quality of life improved over the course of initial therapy, earlier, and to a greater extent.[73]

Sources: 73

The U.S. Food and Drug Administration approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged 2 years and older with previously untreated high-risk classical Hodgkin lymphoma.

The S1826 (NCT03907488) phase III study included both adolescents (aged ≥12 years) and adults. The study evaluated six cycles of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) with either brentuximab vedotin or nivolumab (see Table 6). A total of 970 enrolled patients with newly diagnosed stage III or stage IV Hodgkin lymphoma were randomly assigned to receive either brentuximab vedotin-AVD or nivolumab-AVD. Granulocyte colony-stimulating factor was required for patients who received brentuximab vedotin-AVD and optional for patients who received nivolumab-AVD. The cardioprotectant dexrazoxane was allowed for all patients, per the investigator's choice. Radiation therapy for pediatric patients was based on the end-of-treatment imaging evaluation after completion of six cycles of systemic therapy. The use of the AVD backbone with either agent was to reduce or avoid radiation therapy and reduce the use of alkylating agents.[30]

Sources: S1826 (NCT03907488) · Table 6 · 30

The S1826 (NCT03907488) phase III study included both adolescents (aged ≥12 years) and adults. The study evaluated six cycles of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) with either brentuximab vedotin or nivolumab (see Table 6). A total of 970 enrolled patients with newly diagnosed stage III or stage IV Hodgkin lymphoma were randomly assigned to receive either brentuximab vedotin-AVD or nivolumab-AVD. Granulocyte colony-stimulating factor was required for patients who received brentuximab vedotin-AVD and optional for patients who received nivolumab-AVD. The cardioprotectant dexrazoxane was allowed for all patients, per the investigator's choice. Radiation therapy for pediatric patients was based on the end-of-treatment imaging evaluation after completion of six cycles of systemic therapy. The use of the AVD backbone with either agent was to reduce or avoid radiation therapy and reduce the use of alkylating agents.[30]

Patients aged 12 to 17 years accounted for approximately 24% of the study's total accrual.

About 63% of patients had stage IV disease, 68% had B symptoms, and 29% had bulky disease. There were no differences between the brentuximab-AVD group and the nivolumab-AVD group.

Results for this study were released early at a planned interim analysis because the primary PFS end point crossed the protocol-specified monitoring boundary. However, patients continued to be monitored until a median of 2 years was achieved.

The 2-year PFS rate favored nivolumab-AVD over brentuximab vedotin-AVD (92% vs. 83%, respectively) after a median follow-up of 2.1 years. The hazard ratio (HR) was 0.45 (95% CI, 0.30–0.65).

Less than 1% of patients (n = 7) in either arm received consolidative radiation therapy.

The nivolumab-AVD regimen was tolerated better than the brentuximab-AVD regimen. In this study, 9.4% of patients discontinued nivolumab, while 22.2% of patients discontinued brentuximab. Neuropathy was more frequent in the brentuximab arm. Hypothyroidism and hyperthyroidism were more common in the nivolumab arm (7% and 3%, respectively), but other autoimmune conditions were not seen more frequently in the nivolumab arm.

Three age groups were analyzed (12–17 years, 18–60 years, and >60 years). In all age groups, the 2-year PFS rates were significantly increased with the nivolumab-AVD regimen compared with the brentuximab-AVD regimen.

The S1826 (NCT03907488) phase III study included both adolescents (aged ≥12 years) and adults. The study evaluated six cycles of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) with either brentuximab vedotin or nivolumab (see Table 6). A total of 970 enrolled patients with newly diagnosed stage III or stage IV Hodgkin lymphoma were randomly assigned to receive either brentuximab vedotin-AVD or nivolumab-AVD. Granulocyte colony-stimulating factor was required for patients who received brentuximab vedotin-AVD and optional for patients who received nivolumab-AVD. The cardioprotectant dexrazoxane was allowed for all patients, per the investigator's choice. Radiation therapy for pediatric patients was based on the end-of-treatment imaging evaluation after completion of six cycles of systemic therapy. The use of the AVD backbone with either agent was to reduce or avoid radiation therapy and reduce the use of alkylating agents.[30] › Three age groups were analyzed (12–17 years, 18–60 years, and >60 years). In all age groups, the 2-year PFS rates were significantly increased with the nivolumab-AVD regimen compared with the brentuximab-AVD regimen.

Aged 12–17 years: 95% versus 83%.

Aged 18–60 years: 92% versus 86%.

Aged older than 60 years: 88% versus 65%.

The S1826 (NCT03907488) phase III study included both adolescents (aged ≥12 years) and adults. The study evaluated six cycles of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) with either brentuximab vedotin or nivolumab (see Table 6). A total of 970 enrolled patients with newly diagnosed stage III or stage IV Hodgkin lymphoma were randomly assigned to receive either brentuximab vedotin-AVD or nivolumab-AVD. Granulocyte colony-stimulating factor was required for patients who received brentuximab vedotin-AVD and optional for patients who received nivolumab-AVD. The cardioprotectant dexrazoxane was allowed for all patients, per the investigator's choice. Radiation therapy for pediatric patients was based on the end-of-treatment imaging evaluation after completion of six cycles of systemic therapy. The use of the AVD backbone with either agent was to reduce or avoid radiation therapy and reduce the use of alkylating agents.[30]

The authors suggested that nivolumab-AVD will likely be a new standard therapy for patients with advanced-stage Hodgkin lymphoma.

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Chemotherapy

Evolution of European multicenter trial results

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

European investigators have conducted a series of risk-adapted trials evaluating sex-based treatments featuring multiagent chemotherapy with vincristine, prednisone, procarbazine, and doxorubicin (OPPA)/COPP and IFRT.

Key findings from these trials include the following:

Substitution of cyclophosphamide for mechlorethamine in the MOPP combination results in a low risk of subsequent myelodysplasia/leukemia.[10]

Sources: 10

Omission of procarbazine from the OPPA combination and substitution of methotrexate for procarbazine in the COPP combination (OPA/COMP) results in a substantially inferior EFS.[74]

Sources: 74

Substitution of etoposide for procarbazine in the OPPA combination (OEPA) in boys produces comparable EFS to that of girls treated with OPPA and is associated with hormonal parameters, suggesting lower risk of gonadal toxicity.[75]

Sources: 75

Omission of radiation for patients completely responding (defined as complete resolution or only minor residuals in all previously involved regions using clinical examination and anatomical imaging) to risk-based and sex-based OEPA or OPPA/COPP chemotherapy results in a significantly lower EFS in intermediate-risk and high-risk patients than in irradiated patients (79% vs. 91%), but no difference among nonirradiated and irradiated patients assigned to the favorable-risk group.[24]

Sources: 24

Substitution of dacarbazine for procarbazine (OEPA-COPDAC) in boys produces comparable results to standard OPPA-COPP in girls when used in combination with IFRT for intermediate-risk and high-risk patients.[22][Level of evidence B4]

Sources: 22 · Level of evidence B4

A large, multinational, randomized trial (EuroNet-PHL-C1) investigated whether radiation therapy could be omitted in children (aged <18 years) with intermediate- and advanced-stage classical Hodgkin lymphoma who achieved a morphological and adequate metabolic response to early chemotherapy with OEPA. The trial also studied whether modified consolidation with COPDAC (substituting dacarbazine for procarbazine in COPP) reduced gonadotoxicity.[76][Level of evidence B1]

Sources: 76 · Level of evidence B1

A large, multinational, randomized trial (EuroNet-PHL-C1) investigated whether radiation therapy could be omitted in children (aged <18 years) with intermediate- and advanced-stage classical Hodgkin lymphoma who achieved a morphological and adequate metabolic response to early chemotherapy with OEPA. The trial also studied whether modified consolidation with COPDAC (substituting dacarbazine for procarbazine in COPP) reduced gonadotoxicity.[76][Level of evidence B1]

At a median follow-up of 66.5 months, the 5-year EFS rate was 90.1% (95% CI, 87.5%–92.7%) for patients who responded adequately to early chemotherapy with OEPA followed by COPP or COPDAC.

In the analysis according to protocol treatment, the 5-year EFS rate was 89.9% (95% CI, 87.1%–92.8%) for individuals randomly assigned to COPP (n = 444) versus 86.1% (95% CI, 82.9%–89.4%) for those randomly assigned to COPDAC (n = 448). Similar results were observed in the intent-to-treat analysis.

In a subgroup analysis (unplanned), the 5-year EFS rate among those with adequate early response to OEPA was 91.9% (95% CI, 88.1%–95.9%) with COPP and 82.9% (77.2%–89.0%) with COPDAC, but there was no difference in OS.

A posttreatment semen analysis included 45 men at the 40-month follow-up. COPP appeared to be more gonadotoxic (19 of 23 men were azoospermic) than COPDAC (0 of 22 men were azoospermic). Biomarker analyses that included follicle-stimulating hormone (FSH) and inhibin B also suggested higher prevalence of gonadotoxicity after COPP than COPDAC. Similarly, based on biomarker analyses limited to 113 women, FSH was significantly increased in 55 women who were randomly assigned to receive COPP, compared with 58 women who were randomly assigned to receive COPDAC.

Another EuroNet-PHL-C1 trial investigated whether radiation therapy can be omitted in patients with adequate morphological and metabolic responses to OEPA.[77]

Sources: 77

Another EuroNet-PHL-C1 trial investigated whether radiation therapy can be omitted in patients with adequate morphological and metabolic responses to OEPA.[77]

Among 738 patients with early-stage disease (median follow-up period, 63.3 months), 714 patients were assigned to and received therapy in treatment group 1.

Among the 713 patients in the intention-to-treat group, 440 had adequate responses to two cycles of OEPA and did not receive radiation therapy. The 5-year EFS rate was 86.5% (95% CI, 83.3%–89.8%).

The 5-year EFS rate was 88.6% (95% CI, 84.8%–92.5%) for the 273 patients with adequate responses to chemotherapy who also received radiation therapy.

The study findings suggested that radiation therapy can be omitted in patients with early-stage classical Hodgkin lymphoma who have had adequate responses to OEPA chemotherapy.

An open-label, single-arm, multicenter trial (NCT01920932) evaluated two cycles of AEPA (brentuximab vedotin substituted for vincristine in the OEPA regimen) and four cycles of CAPDAC (brentuximab vedotin substituted for vincristine in the COPDAC regimen) in 77 patients aged 18 years or younger with stage IIB, IIIB, or IV classical Hodgkin lymphoma. Residual node radiation therapy (25.5 Gy) was given at the end of all chemotherapy and only to nodal sites that did not achieve a CR at the early-response assessment after two cycles of therapy.[63][Level of evidence B4]

Sources: NCT01920932 · 63 · Level of evidence B4

An open-label, single-arm, multicenter trial (NCT01920932) evaluated two cycles of AEPA (brentuximab vedotin substituted for vincristine in the OEPA regimen) and four cycles of CAPDAC (brentuximab vedotin substituted for vincristine in the COPDAC regimen) in 77 patients aged 18 years or younger with stage IIB, IIIB, or IV classical Hodgkin lymphoma. Residual node radiation therapy (25.5 Gy) was given at the end of all chemotherapy and only to nodal sites that did not achieve a CR at the early-response assessment after two cycles of therapy.[63][Level of evidence B4]

The 3-year EFS rate (median follow-up, 3.4 years) was 97.4%, and the OS rate was 98.7%.

The AEPA and CAPDAC regimens were well tolerated and allowed for omission of radiation therapy in 35% of the treated patients.

Only 4% of patients experienced grade 3 neuropathy.

Compared with historical controls, residual node radiation volumes in patients requiring radiation were very small, sparing healthy surrounding tissue.

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

Accepted Risk-Adapted Treatment Strategies

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Contemporary trials for pediatric Hodgkin lymphoma involve a risk-adapted, response-based treatment approach that titrates the length and intensity of chemotherapy and dose of radiation based on disease-related factors, including stage, number of involved nodal regions, tumor bulk, the presence of B symptoms, and early response to chemotherapy as determined by functional imaging. In addition, vulnerability related to age and sex is also considered in treatment planning.

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Accepted Risk-Adapted Treatment Strategies

Classical Hodgkin lymphoma, low-risk disease

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Table 7 summarizes the results of treatment approaches used for pediatric patients with low-risk Hodgkin lymphoma.

Sources: Table 7

Table 7. Treatment Approaches for Pediatric Patients With Low-Risk Hodgkin Lymphoma
Chemotherapy (No. of Cycles)aRadiation (Gy)StageNo. of PatientsEvent-Free Survival Rate (No. of Years of Follow-up)Survival Rate (No. of Years of Follow-up)
CS = clinical stage; IFRT = involved-field radiation therapy; N/A = not applicable; No. = number.
aFor more information about the chemotherapy regimens, see Table 6.
bIncluded patients with nodular lymphocyte-predominant Hodgkin lymphoma.
OEPA (2) [24]IFRT (20–35)I, IIA28194% (5)N/A
None11397% (5)
ABVD [78]IFRT (21–35)I–IV20985% (5)97% (5)
ABVE (2-4)b [66]IFRT (25.5)IA, IIA, IIIA1, without bulky disease5191% (6)98% (6)
AV-PC [44]NoneIA, IIA, without bulky disease27879.9% (4)99.6% (4)
Response-based IFRT (21)

Sources: Stage · Table 6 · 24 · 78 · 66 · 44

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Accepted Risk-Adapted Treatment Strategies

Classical Hodgkin lymphoma, intermediate-risk disease

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Table 8 summarizes the results of treatment approaches used for pediatric patients with intermediate-risk Hodgkin lymphoma.

Sources: Table 8

Table 8. Treatment Approaches for Pediatric Patients With Intermediate-Risk Hodgkin Lymphoma
Chemotherapy (No. of Cycles)aRadiation (Gy)StageNo. of PatientsEvent-Free Survival Rate (No. of Years of Follow-up)Survival Rate (No. of Years of Follow-up)
CR = complete response; CS = clinical stage; E = extralymphatic; IFRT = involved-field radiation therapy; N/A = not applicable; RER = rapid early response; SER = slow early response.
aFor more information about the chemotherapy regimens, see Table 6.
OEPA (2) + COPDAC (2) [22]IFRT (20–35)IE, IIB, IIEA, IIIA13988.3% (5)98.5% (5)
ABVE-PC (3–5) [21]IFRT (21)IIA/IIIA, if bulky disease5384% (5)95% (5)
ABVE-PC: RER/CR [20]IFRT (21)IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease38087.9% (4)98.8% (4)
ABVE-PC: RER/CR [20]NoneIB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease38284.3% (4)98.8% (4)
ABVE-PC: SER: +DECA [20]IFRT (21)IB, IAE, IIB, IIAE, IIA, IVA, IA, IIA + bulky disease15379.3% (4)96.5% (4)
ABVE-PC: SER: -DECA [20]IFRT (21)15175.2% (4)94.3% (4)

Sources: Stage · Table 6 · 22 · 21 · 20 · 20 · 20 · 20

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Accepted Risk-Adapted Treatment Strategies

Classical Hodgkin lymphoma, high-risk disease

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Table 9 summarizes the results of treatment approaches used for pediatric patients with high-risk Hodgkin lymphoma.

Sources: Table 9

Table 9. Treatment Approaches for Pediatric Patients With High-Risk Hodgkin Lymphoma
Chemotherapy (No. of Cycles)aRadiation (Gy)StageNo. of PatientsEvent-Free Survival Rate (No. of Years of Follow-up)Survival Rate (No. of Years of Follow-up)
E = extralymphatic; IFRT = involved-field radiation therapy; ISRT = involved-site radiation therapy; N/A = not applicable; No. = number; PFS = progression-free survival.
aFor more information about the chemotherapy regimens, see Table 6.
OEPA (2) + COPDAC (4) [22]IFRT (20–35)IIEB, IIIEA/B, IIIB, IVA/B23986.9% (5)94.9% (5)
ABVE-PC (3-5) [21,79]IFRT (21)IIB, IIIB, IV16385% (5)95% (5)
AEPA (2); CAPDAC (4) [63]Individual residual nodal (25.5)IIB, IIIB, IV7797.4% (3)98.7% (3)
Bv-AVE-PC (5) [53]ISRTIIB + Bulk, IIIB, IV58792.1% (3)99.3% (3)
N-AVD (6) [30]NoneIII, IV487 total (118 aged 12–17 y)PFS: 92% (2)99% (2)

Sources: Stage · Table 6 · 22 · 21 · 79 · 63 · 53 · 30

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Accepted Risk-Adapted Treatment Strategies / Classical Hodgkin lymphoma, high-risk disease

Treatment options under clinical evaluation

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AHOD2131 (NCT05675410) (A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab): This trial compares immunotherapy (brentuximab vedotin and nivolumab) with standard treatment alone for patients with stage I and stage II classic Hodgkin lymphoma.

Sources: AHOD2131 (NCT05675410)

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma / Accepted Risk-Adapted Treatment Strategies

NLPHL

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Table 10 summarizes the results of treatment approaches used for pediatric patients with NLPHL, some of which feature surgery alone for completely resected disease and limited cycles of chemotherapy with or without LD-IFRT. Because of the relative rarity of this subtype, most trials are limited by small cohort numbers and nonrandom allocation of treatment.

Sources: Table 10

Table 10. Treatment Approaches for Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Chemotherapy (No. of Cycles)aRadiation (Gy)No. of PatientsEvent-Free Survival Rate (No. of Years of Follow-up)Survival Rate (No. of Years of Follow-up)
IFRT = involved-field radiation therapy; N/A = not applicable; No. = number.
aFor more information about the chemotherapy regimens, see Table 6.
bSingle lymph node surgically resected.
cAll involved lymph nodes surgically resected.
CVP (3) [65]None5574% (5)100% (5)
Noneb [27]Noneb5277% (5)100% (5)
AV-PC [27]None12485.5% (5)100% (5)
IFRT (21)11
Nonec [28]None5167% (2)100% (2)

Sources: Table 6 · 65 · 27 · 27 · 28

Health professional · Treatment of Newly Diagnosed Children and Adolescents With Hodgkin Lymphoma

Treatment of Adolescents and Young Adults With Hodgkin Lymphoma

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

The treatment approach for adolescents and young adults with Hodgkin lymphoma may vary based on community referral patterns and age restrictions at pediatric cancer centers. The optimal approach is debatable.

In patients with intermediate-risk or high-risk disease, the standard of care in adult oncology practices typically involves at least six cycles of ABVD chemotherapy that delivers a cumulative anthracycline dose of 300 mg/m2.[80,81] For more information, see Hodgkin Lymphoma Treatment. In late-health outcome studies of pediatric cancer survivors, the risk of anthracycline cardiomyopathy has been shown to exponentially increase after exposure to cumulative anthracycline doses of 250 to 300 mg/m2.[82,83] Subsequent need for mediastinal radiation can further enhance the risk of several late cardiac events.[84] In an effort to optimize disease control and preserve both cardiac and gonadal function, pediatric regimens for low-risk disease most often feature a restricted number of cycles of ABVD derivative combinations. For those with intermediate-risk and high-risk disease, alkylating agents and etoposide are integrated into anthracycline-containing regimens.

Sources: 80 · 81 · Hodgkin Lymphoma Treatment · 82 · 83 · 84

No prospective studies of efficacy or toxicity in adolescent or young adults treated with pediatric versus adult regimens have been reported; however, some secondary analyses have been conducted.[85]

Sources: 85

A retrospective review documented the outcomes of patients aged 17 to 22 years treated in the Eastern Cooperative Oncology Group (ECOG) trials E2496 (NCT00003389) or Stanford V versus the COG trial AHOD0031 (NCT00025259).[86][Level of evidence C2]

Sources: E2496 (NCT00003389) · AHOD0031 (NCT00025259) · 86 · Level of evidence C2

A retrospective review documented the outcomes of patients aged 17 to 22 years treated in the Eastern Cooperative Oncology Group (ECOG) trials E2496 (NCT00003389) or Stanford V versus the COG trial AHOD0031 (NCT00025259).[86][Level of evidence C2]

The 5-year failure-free survival (FFS) rates were 68% for patients in the ECOG trial and 81% for patients in the COG trial, with OS rates of 89% and 97%, respectively.

Limitations of this study include differences in the study populations. More adolescents and young adults aged 17 to 22 years in the E2496 study had stage III or IV disease and B symptoms, whereas more adolescents and young adults aged 17 to 22 years in the AHOD0031 study had bulky disease and received radiation (although with smaller doses than those in E2496). Some of these differences were addressed using a propensity score analysis that confirmed inferior FFS for adolescents and young adults in the E2496 trial than those in the AHOD0031 trial. The study was also not a prospective randomized trial.

A comprehensive review of differences in outcomes between adolescent and young adult patients treated in pediatric versus adult trials was published.[87] In a retrospective analysis, adolescents (aged ≥15 years) who were treated in risk- and response-adapted Children’s Oncology Group Hodgkin lymphoma trials had worse EFS and OS rates than children (aged <15 years). These trials included AHOD0431 (NCT00302003) for low-risk patients, AHOD0031 [NCT00025259] for intermediate-risk patients, and AHOD0831 (NCT01026220) for high-risk patients.[88]

Sources: 87 · AHOD0431 (NCT00302003) · AHOD0031 [NCT00025259] · AHOD0831 (NCT01026220) · 88

A comprehensive review of differences in outcomes between adolescent and young adult patients treated in pediatric versus adult trials was published.[87] In a retrospective analysis, adolescents (aged ≥15 years) who were treated in risk- and response-adapted Children’s Oncology Group Hodgkin lymphoma trials had worse EFS and OS rates than children (aged <15 years). These trials included AHOD0431 (NCT00302003) for low-risk patients, AHOD0031 [NCT00025259] for intermediate-risk patients, and AHOD0831 (NCT01026220) for high-risk patients.[88]

After a median follow-up of 7.4 years, the unadjusted 5-year EFS rates were 80% for older patients and 86% for younger patients (HR, 1.38).

The unadjusted 5-year OS rates were 96% for older patients and 99% for younger patients (HR, 2.50). In multivariable modeling, older patients were more likely to die than younger patients (HR, 3.08).

Outcomes varied by histology for older patients. Older patients with non-mixed cellularity histology experienced a significantly increased risk of having an event, compared with younger patients with the same histology (HR, 1.32). Older patients with mixed cellularity had significantly worse unadjusted 5-year EFS rates (77%) than younger patients (94%) (HR, 2.93 unadjusted). This result remained significant after multivariable modeling (HR, 3.72).

The optimal approach for adolescents and young adults with Hodgkin lymphoma is complicated by critical but understudied variables. Factors such as tumor biology, disease control, supportive care needs, and long-term toxicities in adolescents and young adults with Hodgkin lymphoma require further research.

Adolescent and young adult patients with Hodgkin lymphoma should consider participating in a clinical trial. Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Health professional

Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Because children and adolescents with Hodgkin lymphoma have excellent responses to frontline therapy, second-line (salvage) therapy has only been evaluated in a limited capacity. Because primary therapy fails in relatively few patients, no uniform second-line treatment strategy exists for this population.[1]

Sources: 1

Adverse prognostic factors after relapse include the following:[2][Level of evidence C1]

Sources: 2 · Level of evidence C1

The presence of B symptoms (fever, weight loss, and night sweats) and extranodal disease.[3]

Sources: 3

Early relapse (occurring 3–12 months from the end of therapy).[4,5]

Sources: 4 · 5

Inadequate response to initial second-line therapy.[5]

Sources: 5

Children with localized favorable relapses (≥12 months after completing therapy) whose original therapy involved reduced cycles of risk-adapted chemotherapy alone or chemotherapy with low-dose, small-volume radiation therapy (consolidation therapy) have a high likelihood of achieving long-term survival after treatment with more intensive conventional chemotherapy.[6,7]

Sources: 6 · 7

Treatment options for children and adolescents with refractory or recurrent Hodgkin lymphoma include the following:

Chemotherapy and targeted therapy.

Sources: Chemotherapy and targeted therapy

Checkpoint inhibitor therapy.

Sources: Checkpoint inhibitor therapy

Chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT).

Sources: Chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT)

Chemotherapy followed by allogeneic HSCT.

Sources: Chemotherapy followed by allogeneic HSCT

Involved-site radiation therapy (ISRT).

Sources: Involved-site radiation therapy (ISRT)

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Chemotherapy and Targeted Therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Chemotherapy is the recommended second-line therapy. The choice of specific agents, dose intensity, and number of cycles is determined by the initial therapy, disease characteristics at progression/relapse, and response to second-line therapy.

Agents used alone or in combination regimens in the treatment of refractory or recurrent pediatric Hodgkin lymphoma include the following:

Ifosfamide, carboplatin, and etoposide (ICE).[8]

Sources: 8

Ifosfamide and vinorelbine, with or without bortezomib.[9][Level of evidence B4]; [10][Level of evidence C3]

Sources: 9 · Level of evidence B4 · 10 · Level of evidence C3

Ifosfamide, gemcitabine, and vinorelbine.[11][Level of evidence C1]

Sources: 11 · Level of evidence C1

Vinorelbine and gemcitabine.[12]; [13][Level of evidence C2]

Sources: 12 · 13 · Level of evidence C2

Vinorelbine, gemcitabine, and dexamethasone.[14][Level of evidence C1]

Sources: 14 · Level of evidence C1

Etoposide, prednisolone, ifosfamide, and cisplatin (EPIC).[15]

Sources: 15

Cytosine arabinoside, cisplatin, and etoposide (APE).[16]

Sources: 16

High-dose methotrexate, ifosfamide, etoposide, and dexamethasone (MIED).[17]

Sources: 17

Etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (ESHAP).[18]

Sources: 18

Dexamethasone, high-dose cytarabine, and cisplatin (DHAP).[19]

Sources: 19

Rituximab (for patients with CD20-positive disease) alone or in combination with second-line chemotherapy.[20]

Sources: 20

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy.

Sources: Treatment of Recurrent Classic HL

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy.

A phase II trial in 102 adults with Hodgkin lymphoma whose disease relapsed after autologous HSCT showed the following:[21-24]

Sources: 21 · 24

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy. › A phase II trial in 102 adults with Hodgkin lymphoma whose disease relapsed after autologous HSCT showed the following:[21-24]

A complete remission rate of 34% and a partial remission rate of 40% was observed.[21-23]

Sources: 21 · 23

Patients who achieved a complete remission (n = 34) had a 3-year progression-free survival (PFS) rate of 58% and a 3-year overall survival (OS) rate of 73%, with only 6 of 34 patients proceeding to allogeneic HSCT while in remission.

Further follow-up demonstrated a 5-year OS rate of 41% and a PFS rate of 22%. However, patients who achieved a complete remission (38%) had a 5-year OS rate of 64% and a PFS rate of 52%.[24][Level of evidence B4]

Sources: 24 · Level of evidence B4

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy.

The number of pediatric patients treated with brentuximab vedotin is not sufficient to determine whether they respond differently than adult patients. Clearance and volume of brentuximab vedotin significantly correlates with weight (P < .001), and its area under the curve and C max are lower in children than in adults with weekly dosing.[25]

Sources: 25

The Children’s Oncology Group phase I/II AHOD1221 (NCT01780662) study investigated treatment with brentuximab vedotin and gemcitabine in 46 children and young adults with primary refractory Hodgkin lymphoma or early relapse.[26]

Sources: AHOD1221 (NCT01780662) · 26

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy. › The Children’s Oncology Group phase I/II AHOD1221 (NCT01780662) study investigated treatment with brentuximab vedotin and gemcitabine in 46 children and young adults with primary refractory Hodgkin lymphoma or early relapse.[26]

The recommended phase II dose of brentuximab vedotin was 1.8 mg/kg.

Twenty-four of 42 patients (57%; 95% confidence interval [CI], 41%–72%) treated at this dose level experienced a complete response within the first four cycles. Four of 13 patients (31%) with partial response or stable disease had all target lesions with Deauville scores of 3 or less after cycle four. By modern response criteria, these are also complete responses, increasing the complete response to 28 of 42 patients (67%; 95% CI, 51%–80%).

Compared with alternate second-line regimens, brentuximab vedotin with gemcitabine offers the advantage of avoiding agents, such as anthracyclines, alkylators, or epipodophyllotoxins, that are associated with late treatment-related sequelae.

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy.

Several small retrospective studies have evaluated the outcomes of pediatric and young adult patients with refractory or relapsed Hodgkin lymphoma treated with brentuximab vedotin and bendamustine. Overall results demonstrate tolerability, response, and the potential for this combination to serve as a bridge treatment to HSCT.[27,28][Level of evidence C1]

Sources: 27 · 28 · Level of evidence C1

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy. › Several small retrospective studies have evaluated the outcomes of pediatric and young adult patients with refractory or relapsed Hodgkin lymphoma treated with brentuximab vedotin and bendamustine. Overall results demonstrate tolerability, response, and the potential for this combination to serve as a bridge treatment to HSCT.[27,28][Level of evidence C1]

One study evaluated the outcomes of 32 patients (median age, 16 years) who received up to six cycles of treatment with brentuximab vedotin (1.8 mg/kg) on day 1 and bendamustine (90–120 mg/m2) on days 2 and 3.[27]

Sources: 27

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy. › Several small retrospective studies have evaluated the outcomes of pediatric and young adult patients with refractory or relapsed Hodgkin lymphoma treated with brentuximab vedotin and bendamustine. Overall results demonstrate tolerability, response, and the potential for this combination to serve as a bridge treatment to HSCT.[27,28][Level of evidence C1] › One study evaluated the outcomes of 32 patients (median age, 16 years) who received up to six cycles of treatment with brentuximab vedotin (1.8 mg/kg) on day 1 and bendamustine (90–120 mg/m2) on days 2 and 3.[27]

At the end of treatment, the overall response rate was 81%.

The 3-year OS rate was 78.1%, and the 3-year PFS rate was 67%.

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy. › Several small retrospective studies have evaluated the outcomes of pediatric and young adult patients with refractory or relapsed Hodgkin lymphoma treated with brentuximab vedotin and bendamustine. Overall results demonstrate tolerability, response, and the potential for this combination to serve as a bridge treatment to HSCT.[27,28][Level of evidence C1]

A multicenter study from four academic centers evaluated 29 patients (median age, 16 years) who received a median of three cycles of brentuximab vedotin (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of 3-week cycles.[28]

Sources: 28

Brentuximab vedotin. Brentuximab vedotin has been evaluated in adults with Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) indications for brentuximab vedotin in adult patients are as follows: (1) classical Hodgkin lymphoma after failure of autologous HSCT or after failure of at least two previous multiagent chemotherapy regimens in patients who are not autologous HSCT candidates, and (2) classical Hodgkin lymphoma at high risk of relapse or progression, as postautologous HSCT consolidation therapy. For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.There are ongoing trials to determine the toxicity and efficacy of combining brentuximab vedotin with chemotherapy. › Several small retrospective studies have evaluated the outcomes of pediatric and young adult patients with refractory or relapsed Hodgkin lymphoma treated with brentuximab vedotin and bendamustine. Overall results demonstrate tolerability, response, and the potential for this combination to serve as a bridge treatment to HSCT.[27,28][Level of evidence C1] › A multicenter study from four academic centers evaluated 29 patients (median age, 16 years) who received a median of three cycles of brentuximab vedotin (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of 3-week cycles.[28]

Nineteen patients (66%) achieved a complete metabolic response, and 23 patients (79%) achieved an objective response.

The 3-year posttreatment event-free survival rate was 65%, and the OS rate was 89%.

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Checkpoint Inhibitor Therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Treatments that block the interaction between programmed death-1 (PD-1) and its ligands have shown high levels of activity in adults with Hodgkin lymphoma.

Evidence (nivolumab):

The anti–PD-1 antibody nivolumab induced objective responses in 20 of 23 adult patients (87%) with relapsed Hodgkin lymphoma.[29]

Sources: 29

In a phase I/II study of children with refractory malignancies, single-agent nivolumab was tolerable and showed antitumor activity.[30][Level of evidence C3]

Sources: 30 · Level of evidence C3

In a phase I/II study of children with refractory malignancies, single-agent nivolumab was tolerable and showed antitumor activity.[30][Level of evidence C3]

Among ten children with Hodgkin lymphoma, there was one complete response, two partial responses, and five cases of stable disease.

Twenty-eight patients, aged 5 to 30 years, with low-risk relapsed Hodgkin lymphoma were treated with four cycles of nivolumab and brentuximab vedotin. Patients who had a complete metabolic response to this therapy received an additional two cycles of nivolumab and brentuximab vedotin. Patients who had an inadequate response received intensification therapy with two cycles of brentuximab vedotin and bendamustine. Complete metabolic response (Deauville score ≤3) was assessed after the initial four cycles of treatment or after intensification therapy. Those who achieved a complete metabolic response at any time received involved-field radiation therapy after six total cycles of immunotherapy.[31]

Sources: 31

Twenty-eight patients, aged 5 to 30 years, with low-risk relapsed Hodgkin lymphoma were treated with four cycles of nivolumab and brentuximab vedotin. Patients who had a complete metabolic response to this therapy received an additional two cycles of nivolumab and brentuximab vedotin. Patients who had an inadequate response received intensification therapy with two cycles of brentuximab vedotin and bendamustine. Complete metabolic response (Deauville score ≤3) was assessed after the initial four cycles of treatment or after intensification therapy. Those who achieved a complete metabolic response at any time received involved-field radiation therapy after six total cycles of immunotherapy.[31]

After four cycles of nivolumab and brentuximab vedotin, 23 of 28 patients (82%) achieved a complete metabolic response.

Twenty-six of the 28 patients (93%) achieved a complete metabolic response at some time before radiation therapy.

At 31.9 months of follow-up, the 3-year EFS rate was 87%, and the PFS rate was 95%.

The safety profile was consistent with that of each agent used.

In a phase II study, pediatric and young adult patients (70% were <18 years) with standard-risk relapsed or refractory Hodgkin lymphoma were treated with nivolumab and brentuximab vedotin.[32]

Sources: 32

In a phase II study, pediatric and young adult patients (70% were <18 years) with standard-risk relapsed or refractory Hodgkin lymphoma were treated with nivolumab and brentuximab vedotin.[32]

After four induction cycles of nivolumab plus brentuximab vedotin, 59% of patients (23 of 43) achieved a complete metabolic response.

Patients without a complete metabolic response also received intensification therapy with brentuximab vedotin and bendamustine before undergoing autologous HSCT. After intensification therapy and before consolidation therapy, 94% of patients achieved a complete metabolic response.

The FDA approved nivolumab for adult patients with classical Hodgkin lymphoma who have relapsed or progressed after autologous HSCT and brentuximab vedotin or three or more lines of systemic therapy that included autologous HSCT.[29,33]

Sources: 29 · 33

Evidence (pembrolizumab):

The anti–PD-1 antibody pembrolizumab produced an objective response rate of 65% in 31 heavily pretreated adult patients with Hodgkin lymphoma whose disease relapsed after receiving brentuximab vedotin.[34] For more information, see the Treatment of Recurrent Classic HL section in Hodgkin Lymphoma Treatment.

Sources: 34 · Treatment of Recurrent Classic HL

A phase II study of 210 adult patients (median age, 35 years; range, 18–76 years) with refractory/relapsed classical Hodgkin lymphoma who were treated with pembrolizumab reported the following:[35][Level of evidence C3]

Sources: 35 · Level of evidence C3

A phase II study of 210 adult patients (median age, 35 years; range, 18–76 years) with refractory/relapsed classical Hodgkin lymphoma who were treated with pembrolizumab reported the following:[35][Level of evidence C3]

An overall response rate of 69% (95% CI, 62.3%–75.2%), with a complete response rate of 22.4% (95% CI, 6.9%–28.6%).

In a multicenter, nonrandomized, open-label, single-arm phase I/II study, 15 pediatric patients with relapsed or refractory Hodgkin lymphoma were treated with pembrolizumab at a dose of 2 mg/kg every 3 weeks.[36][Level of evidence C1]

Sources: 36 · Level of evidence C1

In a multicenter, nonrandomized, open-label, single-arm phase I/II study, 15 pediatric patients with relapsed or refractory Hodgkin lymphoma were treated with pembrolizumab at a dose of 2 mg/kg every 3 weeks.[36][Level of evidence C1]

Two patients achieved complete responses, and seven patients achieved partial responses, for an overall objective response rate of 60% (95% CI, 32.2%–83.7%).

Adverse events were documented in 97% of the 154 patients enrolled in the study; most were grades 1 to 2 toxicities.

Grades 3 to 5 events, seen in 45% of the cases, consisted mostly of anemia and lymphopenia.

Treatment interruptions were most commonly caused by transaminitis, hypertension, pleural effusion, and pneumonitis.

Two deaths were attributed to drug administration (one resulting from pulmonary edema and the other from pleural effusion and pneumonitis).

The FDA approved pembrolizumab for use in patients with refractory disease or relapse after three or more lines of therapy.

Sources: pembrolizumab

Trials are ongoing to determine the toxicity and efficacy of combining and/or comparing brentuximab vedotin and nivolumab with chemotherapy in pediatric patients with Hodgkin lymphoma.

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Chemotherapy Followed by Autologous HSCT

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Myeloablative chemotherapy with autologous HSCT is the recommended approach for patients who develop refractory disease during therapy or relapsed disease within 1 year after completing therapy.[8,37-39]; [40,41][Level of evidence C1] This approach is also recommended for patients who have recurrent, extensive disease after the first year of completing therapy or for those with recurrent disease after initial therapy that included intensive (alkylating agents and anthracyclines) multiagent chemotherapy and radiation therapy.

Sources: 8 · 37 · 39 · 40 · 41 · Level of evidence C1

The EuroNet-PHL-R1 study enrolled 118 patients in a prospective nonrandomized study to investigate whether presalvage risk factors and fluorine F 18-fludeoxyglucose (18F-FDG) positron emission tomography (PET) response to reinduction chemotherapy could help determine whether chemotherapy alone or chemotherapy with autologous HSCT was needed in pediatric patients with refractory/relapsed Hodgkin lymphoma. All patients were given two cycles of reinduction therapy consisting of ifosfamide, etoposide, prednisolone (IEP) and adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), followed by consolidation with either radiation therapy alone in patients with low-risk disease or high-dose chemotherapy (HDC)/autologous HSCT, with or without radiation therapy for patients with high-risk disease. There were three risk groups:[42]Patients in the R1 subgroup were defined as low risk, were not studied with 18F-FDG PET, and proceeded to radiation therapy. Patients in the R3 subgroup were defined as high risk and all received HDC/HSCT. Patients in the R2 subgroup were defined as low or high risk based on 18F-FDG PET response. If the PET scan was negative with 50% tumor-volume reduction, the patient was defined as low risk and proceeded to radiation therapy. Those with an inadequate 18F-FDG PET response (Deauville score >3) received HDC/HSCT with radiation therapy.For all 118 patients, the 5-year PFS rate was 71.3%, and the OS rate was 82.7%. For the 41 patients in the low-risk group, the PFS rate was 89.7%, and the OS rate was 97.4%. For the 18 patients in the R2 low-risk group who received HDC/HSCT off protocol, the PFS rate was 88.9%, and the OS rate was 100%. For the 59 patients with high-risk disease, the PFS rate was 53.3%, and the OS rate was 66.5%.This trial showed that 18F-FDG PET response-guided therapy in pediatric patients with relapsed/refractory Hodgkin lymphoma can identify patients who may have excellent outcomes without undergoing HSCT.

Sources: 42

The EuroNet-PHL-R1 study enrolled 118 patients in a prospective nonrandomized study to investigate whether presalvage risk factors and fluorine F 18-fludeoxyglucose (18F-FDG) positron emission tomography (PET) response to reinduction chemotherapy could help determine whether chemotherapy alone or chemotherapy with autologous HSCT was needed in pediatric patients with refractory/relapsed Hodgkin lymphoma. All patients were given two cycles of reinduction therapy consisting of ifosfamide, etoposide, prednisolone (IEP) and adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), followed by consolidation with either radiation therapy alone in patients with low-risk disease or high-dose chemotherapy (HDC)/autologous HSCT, with or without radiation therapy for patients with high-risk disease. There were three risk groups:[42]Patients in the R1 subgroup were defined as low risk, were not studied with 18F-FDG PET, and proceeded to radiation therapy. Patients in the R3 subgroup were defined as high risk and all received HDC/HSCT. Patients in the R2 subgroup were defined as low or high risk based on 18F-FDG PET response. If the PET scan was negative with 50% tumor-volume reduction, the patient was defined as low risk and proceeded to radiation therapy. Those with an inadequate 18F-FDG PET response (Deauville score >3) received HDC/HSCT with radiation therapy.For all 118 patients, the 5-year PFS rate was 71.3%, and the OS rate was 82.7%. For the 41 patients in the low-risk group, the PFS rate was 89.7%, and the OS rate was 97.4%. For the 18 patients in the R2 low-risk group who received HDC/HSCT off protocol, the PFS rate was 88.9%, and the OS rate was 100%. For the 59 patients with high-risk disease, the PFS rate was 53.3%, and the OS rate was 66.5%.This trial showed that 18F-FDG PET response-guided therapy in pediatric patients with relapsed/refractory Hodgkin lymphoma can identify patients who may have excellent outcomes without undergoing HSCT.

R1: Patients with relapse longer than 12 months after completion of initial therapy, who had early-stage disease and received two cycles of chemotherapy.

R3: Patients with progression during or up to 3 months after completion of initial therapy.

R2: Patients with all other relapses.

Autologous HSCT has been preferred for patients with relapsed Hodgkin lymphoma because of the historically high transplant-related mortality (TRM) associated with allogeneic transplant.[43] After autologous HSCT, the projected survival rate is 45% to 70%, and the PFS rate is 30% to 89%.[23,40,44,45]; [46,47][Level of evidence C1]

Sources: 43 · 23 · 40 · 44 · 45 · 46 · 47 · Level of evidence C1

Brentuximab vedotin as maintenance therapy, given for 1 year after autologous HSCT in adult patients with high risk of relapse or progression, demonstrated improved PFS in a randomized, placebo-controlled, phase III trial.[48]

Sources: 48

Brentuximab vedotin as consolidation therapy (after autologous HSCT) was evaluated in 67 pediatric patients with relapsed or refractory Hodgkin lymphoma. The median follow-up was 37 months, and the 3-year PFS rate was 85%. About 69% of these patients (46 of 67) received brentuximab vedotin at any point during the pre-HSCT salvage treatment, for either upfront therapy or reinduction therapy.[49]

Sources: 49

A multicenter, open-label, dose-escalation, phase I/II study evaluated the safety, maximum tolerated dose, and pharmacokinetics of brentuximab vedotin. The study identified a recommended phase II dose in 36 pediatric patients with relapsed or refractory classical Hodgkin lymphoma (n = 19) and anaplastic large cell lymphoma (n = 17). Toxicity was manageable (33% of patients had transient, limited-severity peripheral neuropathy), the maximum tolerated dose was not reached, and pediatric pharmacokinetics were similar to that of adults. The recommended phase II dose of brentuximab vedotin, 1.8 mg/m2, was administered for up to 16 cycles (median, 10 cycles) in the phase II arm. In this arm, 47% of Hodgkin lymphoma participants achieved an overall response (33% complete response, 13% partial response), which provided a bridge to HSCT for some patients.[50][Level of evidence C1]

Sources: 50 · Level of evidence C1

The most commonly used preparative regimens for peripheral blood HSCT are either carmustine (BCNU), etoposide, cytarabine, melphalan (BEAM) or cyclophosphamide, carmustine, etoposide (CBV).[38,44,45,47]; [40,41][Level of evidence C1] Carmustine may produce significant pulmonary toxicity.[47]

Sources: 38 · 44 · 45 · 47 · 40 · 41 · Level of evidence C1 · 47

Other noncarmustine-containing preparative regimens have been used, including high-dose busulfan, etoposide, and cyclophosphamide [51] and lomustine, cytarabine, cyclophosphamide, and etoposide (LACE).[52][Level of evidence C1]

Sources: 51 · 52 · Level of evidence C1

Adverse prognostic features for outcome after autologous HSCT include extranodal disease at relapse, bulky mediastinal mass at time of transplant, advanced stage at relapse, primary refractory disease, poor response to chemotherapy, and a positive positron emission tomography (PET) scan before autologous HSCT.[2,44,45,47,53,54]

Sources: 2 · 44 · 45 · 47 · 53 · 54

For more information about transplant, see Pediatric Autologous Hematopoietic Stem Cell Transplant and Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer.

Sources: Pediatric Autologous Hematopoietic Stem Cell Transplant · Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Chemotherapy Followed by Allogeneic HSCT

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

For patients who do not improve after autologous HSCT and patients with chemoresistant disease, allogeneic HSCT has been used with encouraging results.[15,43,55] Investigations of reduced-intensity allogeneic transplant that typically use fludarabine or low-dose total body irradiation to provide a nontoxic immunosuppression have demonstrated acceptable rates of TRM.[56-59]

Sources: 15 · 43 · 55 · 56 · 59

For more information about transplant, see Pediatric Allogeneic Hematopoietic Stem Cell Transplant and Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer.

Sources: Pediatric Allogeneic Hematopoietic Stem Cell Transplant · Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Involved-Site Radiation Therapy (ISRT)

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

ISRT to sites of recurrent disease may enhance local control if these sites have not been previously irradiated. ISRT is generally administered after high-dose chemotherapy and stem cell rescue.[60] For patients who are not responsive to salvage therapy, ISRT may be considered before HSCT.[61,62] Consolidative ISRT is particularly appropriate in the following situations:[1]

Sources: 60 · 61 · 62 · 1

Low-risk patients whose PET scans are negative after standard-dose salvage chemotherapy.

Select standard-risk and/or high-risk patients who are treated with high-dose chemotherapy and HSCT.

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Response Rates for Primary Refractory Hodgkin Lymphoma

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Salvage rates for patients with primary refractory Hodgkin lymphoma are poor even with autologous HSCT and radiation. However, some studies have reported that intensification of therapy followed by HSCT consolidation can achieve long-term survival.

Evidence (response to treatment of primary refractory Hodgkin lymphoma):

In one large series, the 5-year OS rate was 49% for patients with primary refractory Hodgkin lymphoma after receiving aggressive second-line therapy (high-dose chemoradiation therapy) and autologous HSCT.[63]

Sources: 63

In a Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) study, patients with primary refractory Hodgkin lymphoma (progressive disease on therapy or relapse within 3 months from the end of therapy) had 10-year event-free survival (EFS) and OS rates of 41% and 51%, respectively.[4]

Sources: 4

In a study of 53 adolescent patients (like those who participated in the GPOH study), EFS and OS rates were similar.[64] Chemosensitivity to standard-dose, second-line chemotherapy predicted better survival (OS rate, 66%), and tumors that remained refractory to chemotherapy did poorly (OS rate, 17%).[65]

Sources: 64 · 65

Another group reported a PFS rate of 80% post-HSCT for chemosensitive patients, compared with 0% for those with chemoresistant disease.[40]

Sources: 40

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Second Relapse After Initial Treatment With Autologous HSCT

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

In a phase II study, patients (median age, 26.5 years) who had relapsed or refractory disease after autologous HSCT received brentuximab vedotin, with an objective response rate of 73% and a complete remission rate of 34%. Patients who achieved a complete remission (n = 34) had a 3-year PFS rate of 58% and a 3-year OS rate of 73%. Only 6 of 34 patients proceeded to allogeneic HSCT while in remission.[23][Level of evidence B4]

Sources: 23 · Level of evidence B4

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Treatment Options Under Clinical Evaluation

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents / Treatment Options Under Clinical Evaluation

Anti-CD30 chimeric antigen receptor (CAR) T-cell therapy clinical trials

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Preliminary data on CAR T cells targeting CD30 have been published. In a phase I/II trial of 41 adults with multiply relapsed or refractory Hodgkin lymphoma, CD30 CAR T cells were administered after lymphoreduction with bendamustine alone, bendamustine and fludarabine, or cyclophosphamide and fludarabine.[66] Treated patients had a median of seven previous lines of therapy, including brentuximab vedotin, checkpoint inhibitors, and autologous and allogeneic HSCTs. The overall response rate was 72% for the 32 patients with active disease who received fludarabine-based lymphodepletion. For all evaluable patients, the 1-year PFS rate was 36%, and the OS rate was 94%. The CD30 CAR T-cell therapy was well tolerated.

Sources: 66

A number of clinical trials of anti-CD30 CAR T-cell therapy for patients with relapsed Hodgkin lymphoma are listed on ClinicalTrials.gov. The following is an example of a national and/or institutional clinical trial that is currently enrolling patients younger than 18 years:

Sources: ClinicalTrials.gov

RELY-30 (NCT02917083) (CD30 CAR T Cells With or Without Cyclophosphamide and Fludarabine in Treating Participants With Relapsed or Refractory CD30-Positive Lymphoma): Patients aged 12 years and older with relapsed or refractory Hodgkin lymphoma will receive CD30 CAR T-cell therapy after chemotherapy or autologous transplant in this phase I study.

Sources: RELY-30 (NCT02917083)

Health professional · Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents / Treatment Options Under Clinical Evaluation

Other clinical trials

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Anti–PD-1 antibodies being studied in children with Hodgkin lymphoma include the following:

Pembrolizumab (NCT02332668).

Sources: NCT02332668

Health professional

Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Childhood and adolescent survivors of Hodgkin lymphoma may be at risk of developing numerous late complications of treatment related to radiation, specific chemotherapeutic exposures, and surgical staging.[1,2] Adverse treatment effects may impact the following:

Sources: 1 · 2

Reproductive system (male gonadal toxicity and female gonadal toxicity).

Sources: male gonadal toxicity · female gonadal toxicity

Endocrine system (thyroid abnormalities).

Sources: thyroid abnormalities

Cardiovascular system.

Sources: Cardiovascular system

Risk of subsequent benign or malignant neoplasms.

Sources: subsequent benign or malignant neoplasms

Oral/dental health.

Pulmonary function.

Musculoskeletal growth and development.

Immune system.

In the past 30 to 40 years, pediatric Hodgkin lymphoma therapy has changed dramatically to limit exposure to radiation and chemotherapeutic agents, such as anthracyclines, alkylating agents, and bleomycin. When counseling individual patients about the risk of specific treatment complications, the era of treatment should be considered.

In this regard, Childhood Cancer Survivor Study (CCSS) investigators determined the incidence of serious health conditions among 2,996 five-year survivors of pediatric Hodgkin lymphoma (mean age, 35.8 years), compared outcomes by treatment era and strategies, and estimated risks associated with contemporary therapy.[3]

Sources: 3

The cumulative incidence of any grade 3 to 5 conditions by age 35 years was 31.4%. Females were twice as likely as males to experience these conditions (hazard ratio, 2.1).

The decade-specific risk of grade 3 to 5 conditions declined by 20% from the 1970s to the 1990s (P trend = .002).

Compared with survivors who were treated with chest radiation therapy of 35 Gy or higher in combination with an anthracycline or alkylating agent, patients who received contemporary regimens for low- or intermediate-risk disease had an estimated 40% reduction in risk of grade 3 to 5 conditions (HR, 0.6).

The risk of grade 3 to 5 conditions in survivors who had a recurrence or underwent hematopoietic stem cell transplant (HSCT) was substantially elevated and similar to that of survivors treated with high-dose, extended-field radiation therapy.

Table 11 summarizes late health effects observed in Hodgkin lymphoma survivors, followed by a limited discussion of common late effects. For a full discussion of this topic, see Late Effects of Treatment for Childhood Cancer.

Sources: Table 11 · Late Effects of Treatment for Childhood Cancer

Table 11. Treatment Complications Observed in Hodgkin Lymphoma Survivors
Health EffectsPredisposing TherapyClinical Manifestations
ReproductiveAlkylating agent chemotherapyHypogonadism
Gonadal irradiationInfertility
ThyroidRadiation impacting thyroid glandHypothyroidism
Hyperthyroidism
Thyroid nodules
CardiovascularRadiation impacting cardiovascular structuresSubclinical left ventricular dysfunction
Cardiomyopathy
Pericarditis
Heart valve dysfunction
Conduction disorder
Coronary, carotid, subclavian vascular disease
Myocardial infarction
Stroke
Anthracycline chemotherapySubclinical left ventricular dysfunction
Cardiomyopathy
Congestive heart failure
Subsequent neoplasms or diseaseAlkylating agent chemotherapyMyelodysplasia/acute myeloid leukemia
EpipodophyllotoxinsMyelodysplasia/acute myeloid leukemia
RadiationSolid benign and malignant neoplasms
Anthracycline chemotherapyBreast cancer
Oral or dentalAny chemotherapy in a patient who has not developed permanent dentitionDental maldevelopment (tooth or root agenesis, microdontia, root thinning and shortening, enamel dysplasia)
Radiation impacting oral cavity and salivary glandsSalivary gland dysfunction
Xerostomia
Accelerated dental decay
Periodontal disease
PulmonaryRadiation impacting the lungsSubclinical pulmonary dysfunction
BleomycinPulmonary fibrosis
MusculoskeletalRadiation of musculoskeletal tissues in any patient who is not skeletally matureGrowth impairment
GlucocorticosteroidsBone mineral density deficit (osteoporosis)
Multiple sclerotic bone lesions
Osteonecrosis [4]
ImmuneSplenectomyOverwhelming post-splenectomy sepsis

Sources: 4

Health professional · Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy

Male Gonadal Toxicity

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Important concepts related to male gonadal toxicity include the following:

Gonadal irradiation and alkylating agent chemotherapy may produce testicular Leydig cell or germ cell dysfunction, with risk related to cumulative dose of both modalities.

Hypoandrogenism associated with Leydig cell dysfunction may manifest as lack of sexual development; small, atrophic testicles; and sexual dysfunction. Hypoandrogenism also increases the risk of osteoporosis and metabolic disorders associated with chronic disease.[5,6]

Sources: 5 · 6

Testicular Leydig cells are relatively resistant to treatment toxicity compared with testicular germ cells. Survivors who are azoospermic after gonadal toxic therapy may maintain adequate testosterone production.[7-9]

Sources: 7 · 9

Infertility caused by azoospermia is the most common manifestation of gonadal toxicity. Some pubertal male patients will have impaired spermatogenesis before they begin therapy.[10,11]

Sources: 10 · 11

The prepubertal testicle is likely equally or slightly less sensitive to chemotherapy compared with the pubertal testicle. Pubertal status is not protective of chemotherapy-associated gonadal toxicity.[8,9]

Sources: 8 · 9

Chemotherapy regimens that do not include alkylating agents are not associated with male infertility. These regimens include doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine (ABVD); doxorubicin (Adriamycin), bleomycin, vincristine, etoposide (ABVE); vincristine (Oncovin), etoposide, prednisone, doxorubicin Adriamycin (OEPA); or vincristine, doxorubicin (Adriamycin), methotrexate, prednisone (VAMP).

Prednisone and cyclophosphamide (ABVE-PC) and cyclophosphamide, vincristine, prednisone, dacarbazine (OEPA-COPDAC) are titrated to limit alkylating agent dose to below the usual threshold associated with male sterility. Investigations evaluating germ cell function in relation to single alkylating agent exposure suggest that the incidence of permanent azoospermia will be low if the cyclophosphamide dose is less than 7.5 g/m2.[9,12]

Sources: 9 · 12

Chemotherapy regimens that include more than one alkylating agent, usually procarbazine in conjunction with cyclophosphamide (i.e., cyclophosphamide, vincristine [Oncovin], prednisone, procarbazine [COPP]), chlorambucil, or nitrogen mustard (MOPP), confer a high risk of permanent azoospermia if treatment exceeds three cycles.[13,14]

Sources: 13 · 14

For more information, see the Testis section in Late Effects of Treatment for Childhood Cancer.

Sources: Testis

Health professional · Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy

Female Gonadal Toxicity

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Ovarian hormone production is linked to the maturation of primordial follicles. Depletion of follicles by alkylating agent chemotherapy can potentially affect both fertility and ovarian hormone production. Because of their greater complement of primordial follicles, the ovaries of young and adolescent girls are less sensitive to the effects of alkylating agents than the ovaries of older women. In general, girls maintain ovarian function at higher cumulative alkylating agent doses, compared with the germ cell function maintained in boys.

Important concepts related to female gonadal toxicity include the following:

Most females treated with contemporary risk-adapted therapy will have menarche (if prepubertal at treatment) or regain normal menses (if pubertal at treatment) unless pelvic radiation therapy is given without oophoropexy. Current regimens used in pediatric oncology are tailored to minimize the risk of ovarian failure. Data presented below related to pediatric treatment before 1987 [15,16] or adult trials in Europe (European Organisation for Research and Treatment of Cancer H1–H9 trials) [17] are not likely reflective of the expected reproductive outcomes in the current era.

Sources: 15 · 16 · 17

Ovarian transposition to a lateral or medial region from the planned radiation volume may preserve ovarian function in young and adolescent girls who require pelvic radiation therapy for lymphoma.[18] Ovarian transposition did not appear to modify risk of premature ovarian insufficiency in a cohort of 49 long-term survivors of Hodgkin lymphoma enrolled in the St. Jude Lifetime Cohort Study who were treated with gonadotoxic therapy and underwent ovarian transposition before pelvic radiation therapy.[19]

Sources: 18 · 19

The risk of acute ovarian failure and premature menopause is substantial if treatment includes combined-modality therapy with alkylating agent chemotherapy and abdominal or pelvic radiation or dose-intensive alkylating agents for myeloablative conditioning before HSCT.[15,16] The risk of ovarian failure after treatment with contemporary regimens using lower cumulative doses of cyclophosphamide without procarbazine is anticipated to be lower.

Sources: 15 · 16

In the CCSS, investigators observed that Hodgkin lymphoma survivors were among the highest risk groups for acute ovarian failure and early menopause. In this cohort, the cumulative incidence of nonsurgical premature menopause among survivors treated with alkylating agents and abdominal or pelvic radiation approached 30%.[15,16] These patients were treated before 1986, usually with substantially higher doses of alkylating agents than are used in current regimens in the Children's Oncology Group (COG), EuroNet, or other consortiums.

Sources: 15 · 16

A German study demonstrated that parenthood for female survivors of Hodgkin lymphoma was similar to that of the general population, although parenthood was lower for survivors who received pelvic radiation therapy.[20]

Sources: 20

For more information, see the Ovary section in Late Effects of Treatment for Childhood Cancer.

Sources: Ovary

Health professional · Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy

Thyroid Abnormalities

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Abnormalities of the thyroid gland, including hypothyroidism, hyperthyroidism, and thyroid neoplasms, occur at a higher rate among survivors of Hodgkin lymphoma than in the general population.

Hypothyroidism. Risk factors for hypothyroidism include increasing dose of radiation, female sex, and older age at diagnosis.[21-23] CCSS investigators reported a 20-year actuarial risk of 30% of developing hypothyroidism in Hodgkin lymphoma survivors treated with 35 Gy to 44.99 Gy of radiation and 50% for subjects whose thyroid received 45 Gy or more of radiation.Hypothyroidism develops most often in the first 5 years after treatment, but new cases have emerged more than 20 years after the cancer diagnosis.[22]

Sources: 21 · 23 · 22

Hyperthyroidism. Hyperthyroidism has been observed after treatment for Hodgkin lymphoma, with a clinical picture similar to that of Graves' disease.[24] Higher radiation dose has been associated with greater risk of hyperthyroidism.[22]

Sources: 24 · 22

Subsequent neoplasms. Thyroid neoplasms, both benign and malignant, have been reported with increased frequency after neck irradiation. The incidence of nodules varies substantially across studies (2%–65%) depending on the length of follow-up and detection methods used.[21-23] The relative risk (RR) of thyroid cancer is higher among Hodgkin lymphoma survivors (approximately 18-fold for the CCSS Hodgkin lymphoma cohort compared with the general population).[23] Risk factors for the development of thyroid nodules in Hodgkin lymphoma survivors reported by CCSS include time since diagnosis of more than 10 years (RR, 4.8; 95% confidence interval [CI], 3.0–7.8), female sex (RR, 4.0; 95% CI, 2.5–6.7), and radiation dose to thyroid higher than 25 Gy (RR, 2.9; 95% CI, 1.4–6.9).[23] The absolute risk of thyroid cancer is relatively low, with approximately 1% of the CCSS Hodgkin cohort developing thyroid cancer, with a median follow-up of approximately 15 years.[23] A single-institution Hodgkin lymphoma survivor cohort that included both adult and pediatric cases showed a cumulative incidence of thyroid cancer at 10 years from diagnosis of 0.26%, increasing to approximately 3% at 30 years from diagnosis. In this cohort, age younger than 20 years at Hodgkin lymphoma diagnosis and female sex were significantly associated with thyroid cancer.[25]

Sources: 21 · 23 · 23 · 23 · 23 · 25

For more information, see the Thyroid Gland section in Late Effects of Treatment for Childhood Cancer summary.

Sources: Thyroid Gland

Health professional · Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy

Cardiac Toxicity

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Hodgkin lymphoma survivors exposed to doxorubicin or thoracic radiation therapy are at risk of long-term cardiac toxicity. The effects of thoracic radiation therapy are difficult to separate from those of anthracyclines because few children undergo thoracic radiation therapy without the use of anthracyclines. The pathogenesis of injury differs, however, with radiation primarily affecting the fine vasculature of the heart and anthracyclines directly damaging myocytes.[26-28]

Sources: 26 · 28

Survivors of childhood Hodgkin lymphoma older than 50 years experience more than two times the number of chronic cardiovascular conditions and nearly five times the number of more severe (grades 3–5) cardiovascular conditions compared with community controls. Also, survivors have one severe, life-threatening, or fatal cardiovascular condition, on average.[29]

Sources: 29

Cardiac mortality is higher for survivors of adolescent Hodgkin lymphoma than for survivors of young adult Hodgkin lymphoma. This finding was demonstrated in the Teenage and Young Adult Cancer Survivor Study cohort, with standardized mortality ratios (SMR) of 10.4 (95% CI, 8.1–13.3) for those diagnosed at age 15 and 19 years, compared with an SMR of 2.8 (95% CI, 2.3–3.4) for those diagnosed at age 35 to 39 years.[30]

Sources: 30

Applying a model to predict late cardiac toxic effects of therapy, patients with intermediate- and high-risk Hodgkin lymphoma who were treated in four consecutive COG trials between 2002 and 2020 were assessed for risk of grade 3 to grade 5 cardiac disease at 30 years after completion of therapy. Over this time period, the percentage of patients who received mediastinal radiation therapy decreased from 50% to less than 1%, which led to lower cardiac radiation exposure. Anthracycline doses increased from 200 mg/m2 to 300 mg/m2. However, use of the cardioprotectant dexrazoxane increased from 0% to 80%. The results demonstrated the predicted risk of grade 3 to grade 5 cardiac disease at 30 years will decrease from 10% to 6%, which would be highly statistically significant. The 6% incidence of cardiac disease is similar to the predicted 5% incidence for the general population, which questions the necessity of current long-term cardiac monitoring guidelines.[31]

Sources: 31

Health professional · Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy / Cardiac Toxicity

Radiation-associated cardiovascular toxicity

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Late effects of radiation to the heart may include the following:[32-34] The risks to the heart are related to the amount of radiation delivered to different depths of the heart, volume and specific areas of the heart irradiated, total and fractional irradiation dose, age at exposure, and latency period.

Sources: 32 · 34

Late effects of radiation to the heart may include the following:[32-34] The risks to the heart are related to the amount of radiation delivered to different depths of the heart, volume and specific areas of the heart irradiated, total and fractional irradiation dose, age at exposure, and latency period.

Delayed pericarditis.

Pancarditis, including pericardial and myocardial fibrosis, with or without endocardial fibroelastosis.

Cardiomyopathy.

Coronary artery disease.[27,33]

Sources: 27 · 33

Functional valve injury.[27,35]

Sources: 27 · 35

Conduction defects.

Modern radiation techniques allow a reduction in the volume of cardiac tissue incidentally exposed to higher radiation doses. This reduction should lower the risk of adverse cardiac events.

Austrian-German investigators evaluated the development of cardiac disease (via patient self-report supplemented by physician report) in a cohort of 1,132 pediatric Hodgkin lymphoma survivors monitored for a median of 20 years. The 25-year cumulative incidence of heart disease increased with higher mediastinal radiation doses: 3% (unirradiated), 5% (20 Gy), 6% (25 Gy), 10% (30 Gy), and 21% (36 Gy). Valve defects were most common, followed by coronary artery disease, cardiomyopathy, rhythm disorders, and pericardial abnormalities.[35]

Sources: 35

In a study of adult survivors of Hodgkin lymphoma, vigorous exercise lowered the risk of cardiovascular events, independent of the treatment received.[36]

Sources: 36

Emerging data, not confined to patients with Hodgkin lymphoma but inclusive of other pediatric malignancies, suggest that a lower mean heart dose of 10 Gy to 15 Gy should be a goal in contemporary treatment protocols.[28]

Sources: 28

Health professional · Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy / Cardiac Toxicity

Anthracycline-related cardiac toxicity

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Late complications related to anthracycline injury may include subclinical left ventricular dysfunction, cardiomyopathy, and congestive heart failure.[27]

Sources: 27

Increased risk of doxorubicin-related cardiomyopathy is associated with female sex, treatment with cumulative doses of 250 mg/m2 or higher, younger age at time of exposure, and increased time from exposure.[37]

Sources: 37

Prevention or amelioration of anthracycline-induced cardiomyopathy is important because anthracyclines are required in cancer therapy in more than one-half of children with newly diagnosed cancer.[38,39]

Sources: 38 · 39

Dexrazoxane (a bisdioxopiperazine compound that readily enters cells and is subsequently hydrolyzed to form a chelating agent) has been shown to prevent heart damage in adults and children treated with anthracyclines.[40] Studies suggest that dexrazoxane is safe and does not interfere with chemotherapeutic efficacy. Dexrazoxane has been associated with increased hematologic toxicity and typhlitis in children with Hodgkin lymphoma receiving ABVE-PC chemotherapy.[41]

Sources: 40 · 41

A number of trials have studied the risk of subsequent neoplasms following dexrazoxane administration, and none has found a significant association with subsequent neoplasms.[42,43] However, one study found a borderline statistical increase in subsequent neoplasms in patients randomly assigned to receive dexrazoxane. This increase was attributed to the administration of three topoisomerase inhibitors (doxorubicin, etoposide, and dexrazoxane) within 2 to 3 hours of each other.[44]

Sources: 42 · 43 · 44

Studies of cancer survivors treated with anthracyclines have not demonstrated the benefit of enalapril in preventing progressive cardiac toxicity.[45,46]

Sources: 45 · 46

For more information, see the Late Effects of the Cardiovascular System section in Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of the Cardiovascular System

Health professional · Late Effects From Childhood and Adolescent Hodgkin Lymphoma Therapy

Subsequent Neoplasms

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 16, 2025. Captured 2026-09-09.

Series evaluating the incidence of subsequent neoplasms in survivors of childhood and adolescent Hodgkin lymphoma have been published.[47-54]; [55][Level of evidence C1] Many of the patients included in these series received high-dose radiation therapy and high-dose alkylating agent chemotherapy regimens, which are no longer used.

Sources: 47 · 54 · 55 · Level of evidence C1

Subsequent neoplasms comprise two distinct groups:[56,57]

Sources: 56 · 57

Subsequent neoplasms comprise two distinct groups:[56,57]

Myelodysplasia and acute myeloid leukemia (AML) related to chemotherapy. Subsequent hematological malignancy is related to the use of alkylating agents, anthracyclines, and etoposide and exhibit a brief latency period (<10 years from the primary cancer).[58] This excess risk is largely related to cases of myelodysplasia and subsequent AML. A single-study experience suggests that there could be an increase in malignancies when multiple topoisomerase inhibitors are administered in close proximity.[44] Clinical trials using dexrazoxane in childhood leukemia have not observed an excess risk of subsequent neoplasms.[44,59,60]Chemotherapy-related myelodysplasia and AML are less prevalent after contemporary therapy because of the restriction of cumulative alkylating agent doses.[61,62]Among 1,711 intermediate-risk Hodgkin lymphoma survivors treated with response-adapted therapy in the COG AHOD0031 (NCT00025259) trial (median follow-up, 7.3 years), the 10-year cumulative incidence of subsequent malignancy was 1.3%, and the cumulative incidence of secondary myelodysplastic syndrome or AML was 0.2%. Of the three cases of secondary AML, the median time to onset was 2 years (range, 1.8–2.7 years).[63]

Sources: 58 · 44 · 44 · 59 · 60 · 61 · 62 · AHOD0031 (NCT00025259) · 63

Solid neoplasms that are predominately related to radiation. Solid neoplasms most often involve the skin, breast, thyroid, gastrointestinal tract, lung, and head and neck, with risk increasing with radiation dose.[52,54,64]; [55][Level of evidence C1] The risk of a solid subsequent neoplasm escalates with the passage of time after diagnosis of Hodgkin lymphoma, with a latency of 20 years or more. For more information about subsequent thyroid neoplasms, see the Thyroid Abnormalities section.Breast cancer is the most common therapy-related, solid, subsequent neoplasm after treatment of Hodgkin lymphoma:Breast cancer risk after radiation therapy:Breast cancer risk after chemotherapy (includes survivors of Hodgkin lymphoma and other childhood, adolescent, and young adult malignancies):

Sources: 52 · 54 · 64 · 55 · Level of evidence C1 · Thyroid Abnormalities

Subsequent neoplasms comprise two distinct groups:[56,57] › Solid neoplasms that are predominately related to radiation. Solid neoplasms most often involve the skin, breast, thyroid, gastrointestinal tract, lung, and head and neck, with risk increasing with radiation dose.[52,54,64]; [55][Level of evidence C1] The risk of a solid subsequent neoplasm escalates with the passage of time after diagnosis of Hodgkin lymphoma, with a latency of 20 years or more. For more information about subsequent thyroid neoplasms, see the Thyroid Abnormalities section.Breast cancer is the most common therapy-related, solid, subsequent neoplasm after treatment of Hodgkin lymphoma:Breast cancer risk after radiation therapy:Breast cancer risk after chemotherapy (includes survivors of Hodgkin lymphoma and other childhood, adolescent, and young adult malignancies):

The absolute excess risk of breast cancer ranges from 18.6 to 79 per 10,000 person-years, and the cumulative incidence ranges from 12% to 26%, with onset 25 to 30 years after radiation exposure.[51,65-67]

Sources: 51 · 65 · 67

High risk of breast cancer has been found to increase as early as 8 years after radiation exposure, is rare before age 25 years, and continues to increase with time from exposure. Importantly, breast cancer in female childhood cancer survivors typically develops at least 25 years earlier than in the general population and often years before the ages recommended for population-based screening.[51]

Sources: 51

The cumulative incidence of breast cancer by age 40 to 45 years ranges from 13% to 20%, compared with 1% for women in the general population.[51,65,67,68] This risk is similar to that observed for women with a BRCA gene variant, for whom the cumulative incidence of breast cancer ranges from 10% to 19% by age 40 years.[69]

Sources: 51 · 65 · 67 · 68 · 69

The risk of breast cancer in female survivors of Hodgkin lymphoma is directly related to the dose of radiation therapy received over a range from 4 Gy to 40 Gy.[70] Female patients treated with both radiation therapy and alkylating agent chemotherapy have a lower RR of developing breast cancer than women receiving radiation therapy alone.[52,71]

Sources: 70 · 52 · 71

CCSS investigators also demonstrated that breast cancer risk associated with breast irradiation was sharply reduced among women who received 5 Gy or more to the ovaries.[72] The protective effect of alkylating chemotherapy and ovarian radiation is believed to be mediated through induction of premature menopause, suggesting that hormone stimulation contributes to the development of radiation-induced breast cancer.[73]

Sources: 72 · 73

Several cohort studies have demonstrated a dose-related increased risk of breast cancer among female survivors of childhood, adolescent, and young adult cancer treated with anthracycline chemotherapy.[74-77]

Sources: 74 · 77

St. Jude Lifetime Cohort investigators observed that treatment with anthracycline doses of 250 mg/m2 or higher was associated with increased breast cancer risk in survivors who did not have pathogenic (or likely pathogenic) cancer-predisposing variants and who did not receive chest radiation therapy.[77]

Sources: 77

CCSS investigators reported an additive interaction between anthracyclines and chest radiation therapy, as the risk associated with this combination was higher than the sum of the individual risks.[75]

Sources: 75

Evidence for risk of breast cancer after treatment with higher doses of alkylating agents without chest radiation therapy has been conflicting, with one study reporting an increased risk and others not observing this effect.[74,75,78]

Sources: 74 · 75 · 78

The evidence is inconsistent about risks and dose thresholds for breast cancer after treatment with chemotherapy in women who did not receive chest radiation. Shared decision-making is recommended for planning breast cancer surveillance.[79]

Sources: 79

Hereditary syndromes, other than high-risk breast cancer syndromes, and pathogenic variants may modify the effect of radiation exposure on breast cancer risk after childhood cancer.[80,81]

Sources: 80 · 81

A study of women survivors who received chest radiation for Hodgkin lymphoma showed that one of the most important factors in obtaining breast cancer screenings per guidelines was recommendation from their treating physician.[82] Standard guidelines for routine breast screening are available. The COG guidelines recommend annual screening with magnetic resonance imaging and mammography for women beginning 8 years after treatment or at age 25 years, whichever is later.[82]

Sources: 82 · COG guidelines · 82

For more information, see the Subsequent Neoplasms section in Late Effects of Treatment for Childhood Cancer.

Sources: Subsequent Neoplasms

For patients · General Information About Childhood Hodgkin Lymphoma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

If your child has been diagnosed with Hodgkin lymphoma, you may have questions about how serious the cancer is and your child's chances of survival. The likely outcome or course of a disease is called prognosis. The prognosis depends on:

Sources: prognosis

the stage of the cancer (the size of the cancer, including whether the cancer is a larger tumor mass called bulky disease, and whether the cancer has spread below the diaphragm or to more than one group of lymph nodes)

Sources: stage

whether there are B symptoms (fever for no known reason, weight loss for no known reason, or drenching night sweats) at diagnosis

the type of Hodgkin lymphoma

having more than the usual number of white blood cells or anemia at the time of diagnosis

Sources: anemia

whether there is fluid around the heart or lungs at diagnosis

the sedimentation rate or the albumin level in the blood

the child's sex

whether the cancer is newly diagnosed or has recurred (come back)

Sources: recurred

The treatment options also depend on:

whether there is a low, medium, or high risk the cancer will come back after treatment

the child's age

the risk of long-term side effects

Sources: long-term side effects

Most children and adolescents with newly diagnosed Hodgkin lymphoma can be cured.

Sources: cured

Your child's cancer care team is in the best position to talk with you about your child's prognosis.

For patients · Stages of Childhood Hodgkin Lymphoma

Childhood Hodgkin lymphoma is treated according to risk groups.

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Untreated childhood Hodgkin lymphoma is divided into risk groups based on the stage, size of the tumor, and whether the patient has B symptoms (fever, weight loss, or drenching night sweats). The risk group describes the likelihood that Hodgkin lymphoma will not respond to treatment or recur (come back) after treatment. It is used to plan initial treatment.

Sources: risk groups · tumor · fever · respond · recur

Low-risk childhood Hodgkin lymphoma.

Sources: Low-risk childhood Hodgkin lymphoma

Intermediate-risk childhood Hodgkin lymphoma.

Sources: Intermediate-risk childhood Hodgkin lymphoma

High-risk childhood Hodgkin lymphoma.

Sources: High-risk childhood Hodgkin lymphoma

Low-risk Hodgkin lymphoma requires fewer cycles of treatment, fewer anticancer drugs, and lower doses of anticancer drugs than high-risk lymphoma.

Sources: doses

For patients · Stages of Childhood Hodgkin Lymphoma

Sometimes childhood Hodgkin lymphoma does not respond to treatment or comes back after treatment.

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Primary refractory Hodgkin lymphoma is cancer that does not respond to initial treatment.

Recurrent Hodgkin lymphoma is cancer that has recurred (come back) after it has been treated. The lymphoma may come back in the lymph system or in other parts of the body, such as the lungs, liver, bones, or bone marrow.

Sources: lungs · liver · bone marrow

For patients

Treatment Option Overview

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

There are different types of treatment for children with Hodgkin lymphoma.

Children with Hodgkin lymphoma should have their treatment planned by a team of health care providers who are experts in treating childhood cancer.

The following types of treatment may be used:

The following types of treatment may be used:

Chemotherapy

Radiation therapy

Targeted therapy

Immunotherapy

Surgery

High-dose chemotherapy with stem cell transplant

Clinical trials

Clinical trials

Proton beam radiation therapy

Treatment for childhood Hodgkin lymphoma causes side effects and late effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for children with Hodgkin lymphoma.

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

There are different types of treatment for children with Hodgkin lymphoma. You and your child's care team will work together to decide treatment. Many factors will be considered, such as your child's overall health, and whether the tumor is newly diagnosed or has come back.

For patients · Treatment Option Overview

Children with Hodgkin lymphoma should have their treatment planned by a team of health care providers who are experts in treating childhood cancer.

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of childhood Hodgkin lymphoma. The pediatric oncologist works with other pediatric health care providers who are experts in treating children with Hodgkin lymphoma and who specialize in certain areas of medicine. Other specialists may include:

Sources: pediatric oncologist

pediatrician

Sources: pediatrician

medical oncologist and hematologist

Sources: medical oncologist · hematologist

radiation oncologist

Sources: radiation oncologist

pathologist

Sources: pathologist

pediatric nurse specialist

Sources: pediatric nurse specialist

psychologist

Sources: psychologist

social worker

Sources: social worker

child-life specialist

Sources: child-life specialist

fertility specialist

Sources: fertility specialist

The treatment of Hodgkin lymphoma in adolescents and young adults may be different than the treatment for children. Some adolescents and young adults are treated with an adult treatment regimen.

Sources: regimen

For patients · Treatment Option Overview

The following types of treatment may be used:

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment may be used:

Chemotherapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses one or more drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cancer treatment using more than one chemotherapy drug is called combination chemotherapy. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: combination chemotherapy · injected · systemic chemotherapy

The way the chemotherapy is given depends on the risk group. For example, children with low-risk Hodgkin lymphoma receive fewer cycles of treatment, fewer anticancer drugs, and lower doses of anticancer drugs than children with high-risk lymphoma.

Sources: risk group · doses

For more information, visit Drugs Approved for Hodgkin Lymphoma.

Sources: Drugs Approved for Hodgkin Lymphoma

For patients · Treatment Option Overview / The following types of treatment may be used:

Radiation therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: x-rays · radiation · External radiation therapy

Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of external radiation therapy include:

Sources: tissue

Conformal radiation therapy is a type of external radiation therapy that uses a computer to make a 3-dimensional (3-D) picture of the tumor and shapes the radiation beams to fit the tumor.

Sources: Conformal radiation therapy · 3-dimensional

Intensity-modulated radiation therapy (IMRT) is a type of 3-dimensional (3-D) radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles.

Sources: Intensity-modulated radiation therapy · 3-dimensional (3-D) radiation therapy

Radiation therapy may be given, based on the child's risk group and chemotherapy regimen. The radiation is given only to the lymph nodes or other areas with cancer.

Sources: lymph nodes

For patients · Treatment Option Overview / The following types of treatment may be used:

Targeted therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Types of targeted therapy include:

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.Rituximab or brentuximab may be used to treat high-risk, refractory, or recurrent childhood Hodgkin lymphoma.

Sources: Monoclonal antibody · antibodies · immune system · proteins · infusion · radioactive · Rituximab · brentuximab · refractory · recurrent

Proteasome inhibitor therapy blocks the action of proteasomes in cancer cells. Proteasomes remove proteins no longer needed by the cell. When the proteasomes are blocked, the proteins build up in the cell and may cause the cancer cell to die.Bortezomib is a proteasome inhibitor used to treat refractory or recurrent childhood Hodgkin lymphoma.

Sources: Proteasome inhibitor · Bortezomib

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment may be used:

Immunotherapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Immunotherapy uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. Types of immunotherapy include:

Sources: immune system

Immune checkpoint inhibitor therapy: Some types of immune cells, such as T cells, and some cancer cells have certain proteins, called checkpoint proteins, on their surface that keep immune responses in check. When cancer cells have large amounts of these proteins, they will not be attacked and killed by T cells. Immune checkpoint inhibitors block these proteins, and the ability of T cells to kill cancer cells is increased. The following is a type of immune checkpoint inhibitor therapy:

Sources: Immune checkpoint inhibitor · immune cells · T cells · proteins · immune responses

Immune checkpoint inhibitor therapy: Some types of immune cells, such as T cells, and some cancer cells have certain proteins, called checkpoint proteins, on their surface that keep immune responses in check. When cancer cells have large amounts of these proteins, they will not be attacked and killed by T cells. Immune checkpoint inhibitors block these proteins, and the ability of T cells to kill cancer cells is increased. The following is a type of immune checkpoint inhibitor therapy:

PD-1 and PD-L1 inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body's immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells.Pembrolizumab and nivolumab are types of PD-1 inhibitors that may be used in the treatment of childhood Hodgkin lymphoma that has come back after treatment.

Sources: PD-1 · PD-L1 · immune responses · Pembrolizumab · nivolumab

For patients · Treatment Option Overview / The following types of treatment may be used:

Surgery

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Surgery may be done to remove as much of the tumor as possible for localized nodular lymphocyte-predominant Hodgkin lymphoma in children.

Sources: localized · nodular lymphocyte-predominant Hodgkin lymphoma

For patients · Treatment Option Overview / The following types of treatment may be used:

High-dose chemotherapy with stem cell transplant

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: Stem cell transplant · Stem cells · bone marrow · donor

For more information, visit Drugs Approved for Hodgkin Lymphoma.

Sources: Drugs Approved for Hodgkin Lymphoma

For patients · Treatment Option Overview

Clinical trials

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. Because cancer in children is rare, taking part in a clinical trial should be considered.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. Some clinical trials are open only to patients who have not started treatment. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview / Clinical trials

Proton beam radiation therapy

Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 8, 2025. Captured 2026-09-09.

Proton beam therapy is a type of high-energy, external radiation therapy that uses streams of protons (small, positively-charged particles of matter) to make radiation. This type of radiation therapy may help lessen the damage to healthy tissue near the tumor, such as the breast, heart, and lungs.

Sources: Proton beam therapy · protons · breast · lungs